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ABSTRACT 
Autotaxin (ATX) is a member of the nucleotide pyrophosphatase/phosphodiesterase 
family of ectoenzymes (NPP/ENPP). ATX is mostly present in blood, but it is also expressed at 
high levels in the brain, kidney, lymphoid organs, ovary, lung, and intestine. ATX has 
lysophospholipase D activity that catalyzes the hydrolysis of lysophosphatidylcholine (LPC) into 
lysophosphatidic acid (LPA) and choline. LPA is a bioactive lipid mediator that facilitates many 
physiological and pathological processes including cell survival, proliferation, and migration. 
ATX/LPA signalling has been associated with in a number of human diseases including obesity, 
diabetes, rheumatoid arthritis, multiple sclerosis, neuropathic pain, Alzheimer’s disease, and 
cancer. Elevated ATX expression is found in various tumours and has been associated with 
tumour growth. Because most LPA is produced by ATX activity, an inhibitor of ATX would 
block subsequent LPA signalling, which is a target for anticancer drug development. Therefore, 
ATX has become an attractive drug target for developing new anticancer therapies. Our objective 
for this project is to prepare and assess a series of novel cyclic phenol phosphate analogues for 
their ability to function as irreversible ATX inhibitors in vitro.  
In order to investigate the ability of the cyclic phenol phosphate analogues to inhibit 
ATX, the following aims were outlined: (i) the development of synthetic methodologies for the 
preparation of a series of cyclic phenol phosphate analogues as potential inhibitors of ATX; (ii) 
an assessment of the aqueous stability of these analogues over 6 h in 50 mM TRIS buffer at 37 
°C and pH 8.0 using high performance liquid chromatography (HPLC) for analysis; (iii) the 
determination of the ability of these compounds to inactivate ATX in vitro.  
In order to investigate the ability of the cyclic phenol phosphate analogues to inhibit 
ATX, we proposed and designed strategies to synthesize a series of acyl and alkyl ether 
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derivatives of cyclic phenol phosphate analogues. Our initial strategy to synthesize acyl 
derivatives utilized the dealkylation of 1 (4-methoxy-1,3-bezenedimethanol); however, this 
approach was unsuccessful despite attempts to optimize reaction conditions and introduction of 
alcohol protecting groups. These unsuccessful reactions were likely the result of multiple 
competing reactions. A second strategy to synthesize alkyl ether derivatives analogues was 
developed, and we successfully synthesized two model analogues; A1 (unsubstituted cyclic 
phenol phosphate) and A2 (methoxy-substituted cyclic phenol phosphate). We accomplished this 
through a multi-step synthetic procedure using the salicylaldehyde and its derivatives as our 
starting materials. We also synthesized an alcohol starting material with a saturated fourteen-
carbon ether linkage by modified literature procedures, but incorporation of the cyclic phosphate 
moiety was unsuccessful. We also evaluated the stability of the synthesized analogues under 
specific conditions. Analogues A1 and A2 were incubated in 50 mM TRIS buffer at 37 °C and 
pH 8.0 over six hours and determined to be stable under these conditions, suggesting any ATX 
inhibitory activity would be the result of the parent compound rather than any decomposition 
products. Finally, these compounds have been submitted to our colleagues at the University of 
Memphis for assessment of their in vitro ATX inhibitory ability; however, they have not been 
able to carry out the ATX inhibition assay yet. Also, we carried out the preliminary in silico 
docking studies. Our proposed and synthesized analogues of both acyl and alkyl ether derivatives 
of cyclic phosphate analogues were docked to the active site of the ATX (PDB ID: 3NKM) to 
assess their binding affinity. The results of the docking experiment revealed no major 
differences.  However, both A1 and A2 show the highest values (i.e. lowest affinity), which 
indicate that the long side chains of the other ligands play a role in binding to ATX.  
Thus, the proposed cyclic phenol phosphates have not been previously prepared and can 
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therefore represent a new orientation for the study of ATX inhibitor compounds and may lead to 
the development of new treatments for ATX-related human diseases in the future, including 
cancer. 
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CHAPTER 1: INTRODUCTION 
Despite developments in drug discovery of chemotherapeutic agents, cancer still remains 
one of the primary causes of death due to the development of resistance to chemotherapy and the 
recurrence of cancer cells.
1
 Available cancer treatments have shown many disadvantages, such as 
severe side effects and little selectivity to target cancer cells. Therefore, great effort has been 
directed toward the development of improved anti-tumour therapies. 
Autotaxin (ATX) is an extracellular enzyme, and is a member of the nucleotide 
pyrophosphatase/phosphodiesterase family of ectoenzymes (NPP/ENPP) that catalyze hydrolysis 
of phosphodiester bonds of different compounds.
2-4
 The mammalian ENPP family contains seven 
members (ENPP 1–7) and ATX is known as ENPP 2/NPP 2. ATX is a glycoprotein that was first 
isolated from A2058 melanoma cells and classified as an autocrine motility factor in 1992. It was 
later found to be responsible for cell proliferation, survival, migration, and invasion.
5
  
Following the initial disclosure, further investigation by Umezu-Goto et al.
6
 and 
Tokumura et al.
7
 showed that ATX possesses lysophospholipase D (lysoPLD) activity, which is 
responsible for the hydrolysis of lysophosphatidycholine (LPC) to lysophosphatidic acid (LPA) 
and choline.
6, 7
 LPA is a bioactive phospholipid with different functions in many cell types, and 
it can promote a variety of physiological events. It exhibits its action by binding to specific G 
protein-coupled receptors (GPCRs) and stimulating a wide variety of cellular functions, 
including cell proliferation, migration, and survival.
6, 8, 9
 
ATX-mediated formation of LPA is associated with a number of disease states, including 
obesity,
10
 diabetes,
11
 rheumatoid arthritis,
12
 neuropathic pain,
13, 14
 and cancers.
8, 15, 16
 One 
particular area of interest is the relationship between the ATX enzyme and cancer progression. 
 
 
2 
Many studies have investigated the function of ATX-LPA signalling in tumour formation and 
metastasis since the discovery of ATX as the autocrine motility factor for melanoma cells.
3, 4, 17
 
Subsequent experiments have identified the role of ATX in tumorigenesis, cancer progression, 
tumour cell motility, tumour cell invasion, metastatic processes, and angiogenesis.
8, 15, 18-21
 
Overexpression of ATX has been frequently demonstrated in different human tumours,
8, 15, 20, 22
 
including neuroblastoma,
23
 glioblastoma,
24, 25
 hepatocellular carcinoma,
26
 B-cell lymphoma,
27
 
melanoma,
5
 breast cancer,
28
 renal cell carcinoma,
29
 thyroid carcinoma,
30
 and lung cancer.
31
 
As a consequence, intervention in the ATX−LPA signalling cascade has increasingly 
drawn the attention of researchers in an attempt to understand its functions in physiology and 
pathophysiology.
3, 4
 Also, this knowledge is essential in developing new chemical entities that 
could lead to the discovery of novel medicines to treat several pathological conditions. 
Accordingly, a variety of synthetic chemical inhibitors have been designed and synthesized by 
both academic research groups and pharmaceutical industries. Different chemical categories of 
ATX inhibitors have been summarized in recent review articles.
3, 4, 32
 Many of the initial 
inhibitors were lipid-like structures in order to mimic the shape and properties of the natural 
substrate (LPC) or the product (LPA) phospholipids of the enzymatic reaction. Although a 
number of these analogues show potent inhibitory activity, such derivatives usually suffer from 
poor solubility and bioavailability due to the presence of a long lipophilic chain, limiting their 
use for in vivo applications.
4, 32
 More recently, small-molecule inhibitors have been discovered 
through approaches utilizing screening of chemical libraries or have been designed taking the 
crystal structure of ATX into consideration.
4, 32, 33
  
In 2011, a crystal structure of mouse ATX was solved by Nishimasu et al.,
34
 whereas the 
crystal structure of rat ATX was solved by Hausmann et al.
35
 Both crystal structures share 93 % 
 
 
3 
sequence identity with human ATX. This progress has been an important step in understanding 
the ATX binding site and critical interactions required for enzymatic activity, hence helping to 
develop new potent inhibitors for this promising therapeutic target.
3, 32
 Subsequent investigations 
into ATX structure
36-39
 have led to the development of small-molecule compounds that 
demonstrated high inhibitory activities and afforded helpful tools for research; however, 
additional applications in animal model studies have yet to be demonstrated.
4, 32
  
At present, most ATX inhibitors developed are reversible inhibitors. Indeed, only a 
limited number of irreversible inhibitors have been reported. Since the reduction of side-effects 
and low toxicity are major goals of cancer chemotherapy, a potential advantage of irreversible,  
mechanism-based ATX inhibitors is their target specificity. Thus, there is still a need to design 
and synthesize novel, potent, and selective compounds that would provide effective inhibition to 
ATX activity to reduce conversion of LPC to LPA. This inhibition would decrease the unwanted 
cell proliferation, survival, and migration to prevent, or at least reduce, the advance of certain 
cancers. Therefore, our overall goal in this study is to synthesize and assess a series of cyclic 
phenol phosphate analogues and investigate their ability to function as irreversible ATX 
inhibitors. We expect to provide insight into the structure of the enzyme and to understand the 
critical structural features to inhibit ATX activity, which is likely to lead to the development of 
new treatments for human diseases in the future, including cancer. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 History of Autotaxin 
Autotaxin is a glycoprotein enzyme with a molecular mass of 125 kDa.
5
 In 1992, ATX 
was identified as a potent autocrine motility stimulating factor found in the media derived from 
A2058 human melanoma cells. The name ATX is derived from its first property as an autocrine 
motility factor because the A2058 melanoma cells that secrete ATX also respond to ATX itself. 
At that time, the enzymatic activity of ATX was unknown. Two years later, it was found that 
ATX has a significant homology to the nucleotide pyrophosphatase/phosphodiesterase 
(NPP/ENPP) family
40
 found extracellularly as secreted ectoenzymes that catalyze hydrolysis of 
pyrophosphate or phosphodiester bonds in different extracellular compounds such as nucleotides, 
lysophospholipids, and choline phosphate esters.
2
 The mammalian ENPP family contains seven 
members (ENPP 1–7) that are divided into two subclasses (ENPP 1–3 and ENPP 4–7) depending 
on their primary structure; ATX is known as ectonucleotide pyrophosphatase/phosphodiesterase 
2 (ENPP 2 or NPP 2). The mystery remained until 2002, when plasma lysophospholipase D 
(lysoPLD) was purified and found to be identical to ATX.
6, 7, 41
 ATX is unique among 
NPP/ENPP enzymes because of its lysoPLD activity, which hydrolyzes lysophosphatidylcholine 
(LPC) to generate the lipid mediator lysophosphatidic acid (LPA).
6
 ATX has a higher affinity for 
LPC than nucleotides, suggesting that LPC is the preferred physiological substrate for ATX. 
LPA is a bioactive phospholipid with different functions in many cell types, and it exhibits its 
action by binding to specific G protein-coupled receptors (GPCRs) and stimulating a wide 
variety of cellular functions, including migration, proliferation, and survival.
4, 42
 
Furthermore, ATX is expressed in different biological fluids such as plasma, serum, 
seminal plasma, cerebrospinal fluid, urine, and saliva, in both human and animals.
8
 Although 
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ATX is ubiquitous, it is expressed at a high level in the brain, kidney, lymphoid organs, ovary, 
lung, and intestine.
43
 
2.2 ENPP Family  
ATX/NPP 2/ENPP 2 is one of the seven known members of the NPP/ENPP family, 
which are numbered according to their order of discovery.
2
 The ENPP family members can be 
divided into two major subgroups ENPP 1–3 and ENPP 4–7.36 ATX/ENPP 2 shares a common 
structure with NPP 1 and NPP 3; therefore, they have a domain structure composed of two N-
terminal somatomedin B-like (SMB) domains, a central catalytic phosphodiester (PDE) domain 
containing a series of determinants that are important for catalysis, and a C-terminal nuclease-
like (NUC) domain.
2, 19, 36, 43
 Even though it has been asserted that the NUC domain is important 
for the lysoPLD activity, the function of the NUC and SMB domains are generally unknown.
34
 
The second subgroup, ENPP 4–7, has only the PDE domain and lacks the SMB and NUC 
domains.
2, 36
 Although these enzymes share the same catalytic domain, which belongs to the 
alkaline phosphatase superfamily, the mammalian ENPP family members have various 
physiological roles according to their particular substrate.  
ATX/ENPP 2 is a secreted protein and the only member that exhibits lysoPLD activity 
and participates in LPA signalling. The other ENPP family members are transmembrane 
proteins, and they can be either type-I (ENPP 4–7) or type-II (ENPP 1–3). Of these members, 
ATX is the best described so far. ENPP 1 is an ectoenzyme that catalyzes hydrolysis of 
extracellular nucleotides to release inorganic pyrophosphate (Ppi), which plays an important role 
in calcification. ENPP 6 and ENPP 7 are choline-specific ecto-phospholipases C, probably 
serving catabolic functions. However, the functions of ENPP 4 and ENPP 5 have not yet been 
identified.
2
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2.3 Overview of the Crystal Structures of Autotaxin 
2.3.1 Overall Architecture 
In 2011, two different research groups presented the crystal structures of mouse
34
 and 
rat
35
 ATX both alone and in complex with different molecules.
4, 39
 The overall structures of 
mouse ATX (Figure 2-1) and rat ATX in various crystal structure forms are virtually identical
39
 
and 93 % identical to human ATX.
34, 35
 Briefly, the ATX structure encompasses four domains: 
two N-terminal somatomedin B-like domains 1 and 2 (SMB1 and SMB2), a central catalytic 
phosphodiesterase (PDE) domain, and a C-terminal nuclease-like domain (NUC) (Figure 2-2).
4, 
39
 The structure of the individual domains of ATX consists of known folds. Also, two linker 
regions are present: the L1 linker region links both the SMB-like domain 2 and the catalytic 
domain, whereas the L2 linker (or lasso loop) region links both the catalytic PDE domain and the 
NUC domain (Figure 2-2).  
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Figure 2-1: Crystal structure of mouse Autotaxin
44
 (PDB ID Code: 3NKM at 2.0 Å Resolution). 
 
 
 
Figure 2-2: Overall architecture of ATX and domain organization. (Adapted from4)   
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2.3.2 Somatomedin B-like Domains of ATX  
The SMB1 and SMB2 are found in all ATX isoforms; they form a disulfide-bonded knot 
fold in which eight cysteine residues are stabilized by four intermolecular disulfide linkages.
34, 39
 
Although there is low sequence identity (15 %) between both SMB-like domains, they are highly 
similar. The structure of SMB-like domains of ATX is similar to the SMB domain of vitronectin 
(PDB ID 1OC0), an extracellular matrix protein that regulates tumour cell adhesion and 
migration by the interaction of its SMB domain with urokinase-type plasminogen activator 
(uPAR) receptor and plasminogen activator inhibitor-1 (PAI-1).
45
 The disulfide bond pattern is 
preserved as well among the three domains; however, the amino acid residues of the vitronectin 
SMB domain, which interacts with PAI-1 and uPAR, are not preserved in the ATX SMB-like 
domains, indicating that the function of the ATX SMB domain is not interacting with PAI-1 and 
is different from other SMB domains. 
2.3.3 Catalytic Phosphodiesterase Domain and the Active Site 
The central catalytic phosphodiesterase (PDE) domain interacts with both SMD and NUC 
domains, and it contains the active site for hydrolysis of nucleotides and lysophospholipids 
(Figure 2-2).
4
 The ATX active site contains threonine (Thr) as a nucleophile, and two zinc ions 
(Zn
2+
). The key residue in the active site of mouse and rat ATX is Thr209,
4, 34, 35
 whereas the 
active residue in human ATX is Thr210.
4, 46
 The Thr209 and the two Zn
2+ 
ions are coordinated 
by conserved aspartate (Asp) and histidine (His) residues.
4, 34, 39
 Significantly, the first Zn
2+ 
ion
 
is 
coordinated by Asp311, His315, and His474, whereas the second Zn
2+ 
ion
 
is coordinated by 
Asp171, Thr209, and His359. These Zn
2+
 ions are vastly conserved among the ENPP family 
members and are important for lysoPLD activity of ATX and ENPP 1.
34
 The catalytic domain of 
ATX and ENPP 1 has a similar structure to a bacterial NPP enzyme from Xanthomonas 
 
 
9 
axonapodis (XaNPP; PDB ID 2GSU).
47
 Both the catalytic residues and the two Zn
2+ 
ions
 
are 
found at the same location in ATX and XaNPP, indicating that they have a similar catalytic 
mechanism. In addition to the coordinating residues and the two Zn
2+ 
ions, the preserved 
Asparagine (Asn) Asn230 and Tyrosine (Tyr) Tyr306 of ATX superimpose with Asn111 and 
Tyr206 of XaNPP, respectively.
34
 These investigations support the hypothesis that ATX 
catalyzes LPC by the same catalytic mechanism as XaNPP.  
2.3.4 A Shallow Groove and a Deep Hydrophobic Pocket 
The catalytic sites are nearly identical in ATX, ENPP 1, and XaNPP.
38
 All of them 
encompass the Thr nucleophile with two Zn
2+ 
ions, coordinated by Asp and His residues. These 
Zn
2+ 
ions participate in bond-breaking steps.
37
 Additionally, all three enzymes possess a shallow 
groove that is capable of binding nucleotide substrates. 
Moreover, the PDE domain encompasses a hydrophobic lipid-binding pocket, which is 
unique for ATX among the ENPP family and any other phospholipase enzyme.
38, 48
 The pocket, 
which is about 15 Å deep, is located inside the hydrophobic core of the catalytic domain down 
from the shallow groove.
37, 38
 Formation of this pocket in ATX is due to the absence of 18 amino 
acid residues in ATX that are found in all other ENPPs and the bacterial NPP enzyme. Therefore, 
the absence of these sequences leads to the formation of the pocket in ATX, which allows ATX 
to function as a lysoPLD. Furthermore, this pocket can accommodate various LPA and LPC 
species with different chain lengths and saturations in particular conformations.
4, 38
 Specifically, 
the short chain saturated molecules, 14:0 and 16:0 LPA, can be accommodated in the 
hydrophobic pocket, whereas 18:0 does not seem to fit.
38
 Conversely, the unsaturated LPA 
species such as 18:1 and 18:3 can bend at the unsaturated bonds, whereas 22:6 adopts a U-
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shaped conformation inside the pocket. 
2.3.5 Tunnel of Autotaxin 
ATX appears to have a hydrophobic tunnel or channel that forms a T-junction with the 
substrate-binding pocket.
4, 37, 38
 This tunnel is located between the SMB1 and catalytic PDE 
domain. The absence of the 18 amino acids in ATX is also responsible for formation of this 
tunnel, which makes it a unique characteristic of ATX that is not present in other NPPs. The 
tunnel can accommodate the hydrophobic tail of lysophospholipids; therefore, it is possible that 
the hydrophobic tunnel can serve as an entrance for the LPC to the catalytic site and as an exit 
for the LPA, allowing the delivery of LPA to its adjacent GPCRs.  
2.3.6 Nuclease-Like Domain  
The C-terminal nuclease-like domain (NUC) is catalytically inactive.
37
 The NUC domain 
is strongly bound to the PDE domain by a 50-residue lasso loop, which starts at the end of the 
PDE domain and binds tightly with the NUC domain (Figure 2-2).
35
 This binding is reinforced 
through seven hydrogen bonds, nine salt bridges, and an intramolecular cysteine bridge; together, 
these maintain the structural rigidity of ATX. These observations demonstrate the important role 
of the interaction between both the catalytic PDE and the NUC domain for lysoPLD activity of 
ATX.  
In summary, the crystal structures of mouse ATX and rat ATX are virtually identical and 
are 93 % identical to human ATX. The ATX structure encompasses four domains:  the two N-
terminal SMB1 and SMB2 domains, the central catalytic PDE domain that contains the catalytic 
active site, and the C-terminal NUC domain. The active catalytic site of ATX contains the Thr 
nucleophile and two Zn
2+ 
ions. Also, the PDE domain encompasses a hydrophobic lipid-binding 
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pocket, which is unique to ATX among the ENPP family. This pocket can accommodate various 
LPA and LPC species with different chain lengths and saturations in particular conformations. 
Also, ATX has a hydrophobic tunnel that can accommodate the hydrophobic tail of 
lysophospholipids. 
2.4 Domain Arrangement  
The modular domain arrangement of the ATX enzyme has been identified. The catalytic 
PDE domain extensively binds to both the SMB-like domains from one side and to the NUC 
domain from the other side, with the L1 and L2 linkers reinforcing the whole molecule (Figure 
2-2).
34
 The domain arrangement is stabilized by a number of hydrophobic and hydrophilic 
interactions. Similarly, the arrangement of water molecules in a specific order between the 
catalytic PDE and NUC domains develops a huge network of hydrogen bonds.
34
 The L1 linker 
connects to the catalytic PDE domain, whereas the L2 linker connects with both catalytic PDE 
and NUC domains. These interactions are combined by the four disulfide bonds. Many of the 
residues that participate in the interdomain interactions are preserved among the ATX enzymes 
from various organisms, indicating the biological importance of the observed domain 
arrangement. In fact, these residues are also extensively preserved between ENPP 1–3, 
suggesting that the domain arrangement is similar among them. 
2.5 Human Autotaxin  
Rat, mouse, and human ATX proteins have about 93 % sequence identity.
4, 34, 35
 Residue 
numbers in the human enzyme are n+1 in comparison to the mouse/rat enzyme because of the 
insertion of an additional amino acid after residue number 37. However, the important functional 
amino acids residues and their domains are extensively conserved among them. Furthermore, the 
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ATX enzymes exhibit similar activities toward LPC substrates. These findings suggest that they 
have almost the exact same structures. Therefore, the crystal structure of rat/mouse ATX can be 
used as a starting point to design and develop new inhibitors of the human ATX enzyme. 
2.6 Substrate Specificity  
The substrate specificity of the ENPP family is quite varied. Specifically, ENPP 1–3 can 
identify nucleotides and their derivatives.
2
 In the case of ATX, it recognizes lysophospholipids in 
addition to nucleotides. ENPP 6 and ENPP 7 identify phosphate ester substrates like LPC, but 
they hydrolyze LPC to monoacylglycerol and choline phosphate. The substrates of ENPP 4 and 
ENPP 5 are still unknown.   
In particular, a number of substrates of ATX/ENPP 2 have been recognized including 
phosphodiester, phosphonate esters, sulfo–phosphates, and phospholipids. However, the 
biological effect of ATX action depends on several factors.
43, 49
 These factors include ATX 
concentration, substrate availability, presence of regulatory cofactors, and the spectrum of LPA 
expressed on adjacent target cells. Specifically, regulation of ATX expression can be controlled 
by different factors such as cytokines, oncogenes, and growth factors. Nevertheless, these factors 
appear to depend on the cell type.
50
 ATX produces LPA from extracellular LPC and other non-
choline lysophospholipids such as lysophosphatidylserine (LPS) and 
lysophosphatidylethanolamine (LPE).
38, 51
 Although several compounds have been reported to be 
substrates of ATX, LPC is the major physiological substrate for ATX.
8, 19, 43
 LPC is the most 
abundant phospholipid in blood plasma where its concentration in human reaches about 200 
μM.52, 53 However, the abundant LPC in the circulation is relatively inactive unless it is 
transformed to LPA by ATX.
15
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In addition to LPC, ATX can also hydrolyze sphingosylphosphorylcholine (SPC) to 
produce sphingosine-1-phosphate (S1P), a bioactive lipid mediator, in vitro
49
 (Scheme 2-1). 
However, the catalytic ability of ATX to hydrolyze SPC to S1P is 4.5 times less than the 
catalytic efficiency for hydrolysis of LPC to LPA. Thus, it does not seem that ATX contributes 
in the major pathway to formation of S1P in vivo.
54
 Furthermore, Tanaka et al.
55
 confirmed that 
ATX is the main enzyme for producing LPA in blood, but not for production of S1P. It has been 
reported that S1P can also be produced intracellularly by the action of sphingosine kinase.
49, 55
 
Indeed, it is probable that other lipid-like molecules and possibly lysophospholipids are 
substrates of ATX. 
Furthermore, ATX can also hydrolyze nucleotides and their derivatives in vitro such as 
adenosine-5′-triphosphate (ATP), diadenosine polyphosphates (ApnA), uridine diphosphate 
glucose (UDP-glucose), nicotinamide adenine dinucleotide (NAD
+
), and p-nitrophenyl 
thymidine-5′-monophosphate (pNTM).4, 56 Although ATX is able to hydrolyze nucleotides in 
vitro, the affinity of ATX for LPC is about 10-fold higher than for nucleotides.
38
 Therefore, ATX 
may not hydrolyze nucleotides in vivo.  
Obviously, the ENPP family recognizes a wide variety of substrates. Particularly, several 
compounds have been identified as substrates for ATX. However, the major physiological 
substrate for ATX is LPC, which is the most abundant phospholipid in blood plasma.   
 
Scheme 2-1: Hydrolysis of SPC to S1P by ATX. 
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2.7 Autotaxin Isoforms 
In 2008, three isoforms of ATX (α, β, and γ) and their tissue distribution were described 
in human and mouse
4, 32, 57
 and an additional two (δ and ε) in 2012 (Figure 2-3).4, 58 ATXα was 
the first identified isoform; it was originally isolated from human melanoma cells as the 
autocrine motility factor.
5
 ATXα consists of 915 amino acids, the longest isoform, and it is 
characterized by a 52-amino acid insertion in the central catalytic domain.
4, 57
 ATXα exhibits the 
lowest expression levels of all isoforms, both in the central nervous system and the peripheral 
tissues. ATXβ was originally cloned from a teratocarcinoma cell line, and it is the best studied 
isoform that is identical to plasma lysoPLD.
4, 7
 ATXβ consists of 863 amino acids and is the 
most abundant isoform that is highly expressed in the peripheral tissues. Virtually all studies on 
ATX use this isoform.
38
 A third isoform, ATXγ, was identified as an ecto-phosphodiesterase 
I/nucleotide pyrophosphatase (PD-Iα).4, 23 ATXγ contains 888 amino acids and is mostly 
expressed in the central nervous system with low expression in the peripheral tissues.
57
 ATXγ 
lacks the same 52-residue insertion found in ATXα although contains an additional 25 amino 
acids in the NUC domain of the protein. ATXδ is made up of 859 amino acids and has a four-
amino acid deletion in the L2 linker region of ATXβ. ATXδ was found to be the second major 
isoform following ATXβ, and it has very similar biochemical characteristics to ATXβ. Finally, 
ATXε consists of 911 amino acids and is a less abundant isoform such as ATXα.4 ATXε is 
characterized by insertion of 52 amino acids in the catalytic domain, similar to ATXα, along with 
the four-amino acid deletion in the L2 linker region (Figure 2-3). Overall, all ATX isoforms 
exhibit similar activities of lysoPLD and substrate preferences.
38
 Currently, it is unclear whether 
any of the ATX isoforms have unique physiological or pathophysiological functions. 
In fact, five ATX isoforms and their tissue distribution have been determined in human 
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and mouse. ATXβ is the most abundant isoform, and it is identical to plasma lysoPLD. All 
current understanding of ATX is derived from studies of ATXβ; however, all ATX isoforms 
reveal the same lysoPLD activities and substrate preferences. 
 
Figure 2-3: Schematic representation of ATX isoforms: α, β, γ, δ, and ε. (Adapted from4)  
 
2.8 The Catalytic Mechanism of ENPPs  
As mentioned previously, the ATX enzyme is one of the members of the widely 
distributed ENPPs family.
6, 8
 These enzymes are known to hydrolyze both pyrophosphate bonds 
and phosphodiester bonds to produce monophosphate.
59
 It has been suggested that the catalytic 
domain of ENPPs has a similar structure to the superfamily of phosphor- or sulfo-related 
metalloenzymes, including alkaline phosphatases.
2, 43, 60
 The comparison of sequence with 
alkaline phosphatase indicates that the catalytic mechanism of ENPPs is similar and occurs in 
two stages. In the first stage of catalysis, an active hydroxyl group (OH) in the catalytic site 
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residue (Thr210 nucleophile in the case of ATX/ENPP 2) attacks the phosphate group of the 
LPC substrate, leading to the formation of a covalent phosphate ester linkage intermediate 
(Scheme 2-2). In the second stage of catalysis, the enzyme intermediate undergoes attack by 
water and loss of the choline, leading to the release of the phosphorylated compound LPA. 
 
Scheme 2-2: Hydrolysis of LPC by ATX.  
2.8.1 Production of LPA by Autotaxin 
Generally, ATX is responsible for production of most of the LPA in the blood.
55
 It has 
been found that ATX acts as an extracellular lysoPLD that transforms LPC, the main substrate of 
ATX, into LPA and choline.
6
 LPA is a bioactive form of lysophospholipid that activates cell 
proliferation, cell survival, migration, and angiogenesis of various cells through activation of 
GPCRs (Figure 2-4).  
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Figure 2-4: ATX is Responsible for Hydrolyzing LPC into LPA and Choline in an Extracellular 
Environment. (Adapted from
17, 36
)  
 
2.9 Lysophosphatidic Acid  
Lysophosphatidic acid (1-acyl-glycerol 3-phosphate; LPA) is a simple, natural 
phospholipid that is composed of a phosphate, a glycerol, and a fatty acid
8, 9
 (Figure 2-5). 
Originally, LPA was known as an intermediate for de novo lipid membrane biosynthesis. Later, 
it was recognized as an intracellular lipid mediator that stimulates different cellular functions in 
several cell types. LPA is involved in numerous biological actions, including smooth muscle 
contraction, platelet aggregation, stimulation of cell proliferation, migration, survival, 
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angiogenesis, and chemotaxis.
8, 9
 It has also been shown to prevent apoptosis. In addition, LPA 
can be found in different biological fluids, such as plasma, serum, seminal fluid, cerebrospinal 
fluid, saliva, and urine, both in humans and animals.
8
 LPA is present in human plasma at a 
concentration of about 0.1 μM.61, 62  
 
Figure 2-5: Chemical structure of lysophosphatidic acid, LPA. 
2.9.1 LPA Production 
 At least two pathways are hypothesized for LPA production.
51, 61, 63
 In the first pathway, 
lysophospholipids (LPLs) such as lysophosphatidylcholine (LPC), 
lysophosphatidylethanolamine (LPE), and lysophosphatidylserine (LPS) are formed by secretory 
phospholipase A2 group IIA (sPLA2-IIA) and phosphatidylserine-specific phospholipase A1 (PS-
PLA1) in the platelets, whereas LPC is generated from phosphatidylcholine (PC) in lipoprotein 
by lecithincholesterol acyltransferase (LCAT) and phospholipase A1 (PLA1)-like enzymes in the 
plasma. LPLs thus produced are subsequently converted to LPA by ATX by its lysoPLD activity. 
This pathway produces the major amount of the serum LPA. In the second pathway, 
phosphatidic acid (PA) is first produced from phospholipids (PLs) or diacylglycerol (DAG) by 
phospholipase D (PLD) or diacylglycerol kinase (DGK), respectively, and then subsequently 
converted to LPA by PLA1 or PLA2 enzymes. However, this pathway produces only a small 
amount of LPA that contributes to its serum production.
61
 Therefore, ATX is significantly 
associated with formation of LPA in serum in the first pathway, and it is the enzyme that 
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displays lysoPLD activity in blood; thus, it can be concluded that ATX is the major enzyme of 
LPA production in serum. 
2.9.2 LPA Receptor Diversity and signalling 
LPA exerts its various actions through GPCRs that are specific for LPA.
8, 51
 At least six 
GPCRs for LPA receptors (LPA1-6) have been recognized and can be classified into two 
subgroups, depending on their primary structure. The first group is the classical LPA receptors 
(LPA1-3) that are related to an endothelial differentiation gene (EDG) family such as 
LPA1/EDG2, LPA2/EDG4, and LPA3/EDG7, and they share about 50 % sequence homology 
with each other. The second subgroup (LPA4-6) consists of LPA4/P2Y9/GPR23, LPA5/GPR92, 
and LPA6/P2Y5. These receptors belong to a purinergic receptor (P2Y) family whose members 
target nucleotides rather than LPLs, and they share about 35 % amino acid identity. Recently, 
GPR87 and P2Y10 were reported to respond to LPA, although further study is required to 
validate these observations.  
All LPA receptors are coupled with different GPCRs (Gi, Gq, Gs, and G12/13) that vary in 
their tissue distribution and signalling pathways.
8, 64
 Specifically, LPA1 is the first receptor 
recognized for LPA.
42, 64
 LPA1 is widely distributed in the brain, uterus, testis, lung, small 
intestine, heart, stomach, kidney, spleen, thymus, placenta, and skeletal muscle in both mice and 
humans. LPA1 is known to interact with and activate Gi, Gq, and G12/13. Activation of the LPA1 
receptor leads to stimulation of a range of cellular responses such as cell proliferation and 
survival, cell migration, cytoskeletal changes, Ca
2+
 mobilization, and adenylyl cyclase inhibition. 
The expression of LPA2 is more restricted compared to LPA1. LPA2 is highly expressed in the 
kidney, uterus, testis, and leukocytes. Similar to LPA1, LPA2 interacts with Gi, Gq, and G12/13, and 
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activation of LPA2 signalling is associated with cell survival and cell migration. Moreover, LPA3 
is highly distributed in the human heart, testis, prostate, and pancreas as well as mouse lung, 
kidney, uterus, and testis. LPA3 can interact with Gi and Gq to stimulate Ca
2+
 mobilization and 
adenylyl cyclase inhibition. Furthermore, LPA4 is expressed at a relatively high level in the 
ovary. LPA4 couples to Gi, Gq, Gs, and G12/13, and mediates an increase in intracellular cAMP 
levels and Ca
2+
 mobilization. Additionally, LPA5 is highly distributed in the spleen and small 
intestine. LPA5 interacts with Gq and G12/13 and mediates stress fiber formation and increased 
intracellular Ca
2+
 levels and cAMP. In contrast, LPA6 couples to G12/13 and is expressed in hair 
follicles.
8
 LPA6 was recognized as an important mediator for human hair growth and is a 
causative gene for human hair loss.
64
  
2.10 Pathological Role of Autotaxin with Disease States  
The ENPP family can hydrolyze an extensive range of substrates, and they influence 
multiple physiological processes.
65
 It has been observed that dysfunction of ENPP members is 
involved in the pathophysiology of numerous disease states. Specifically, ATX has been 
involved in a number of human diseases including obesity, diabetes, rheumatoid arthritis, 
multiple sclerosis, neuropathic pain, Alzheimer’s disease, and cancer.16 Because ATX and LPA 
are expressed in various biological fluids, they can be used as potential biomarkers to make 
predictions about certain diseases.
8
 From a clinical point of view, the level of ATX seems to 
reflect the pathophysiological status in different disorders. In particular, the serum concentration 
and the activity of ATX are elevated in patients with chronic liver diseases; however, ATX 
declined in patients with postoperative prostate cancer. Also, Tokumura et al.
66
 found that 
lysoPLD activity elevated gradually in women throughout pregnancy. Further, ATX/lysoPLD 
activity relatively increased in the peritoneal fluid of patients with ovarian cancer, compared to 
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the serum lysoPLD activity among healthy individuals.
67
 Although ATX can be detected in the 
urine of nephrosis patients, the serum ATX level is not affected in these patients.
68
 
2.10.1 Pathological Role of LPA/ATX in Cancer 
One particular area of interest is the relationship between the ATX enzyme and cancer 
progression. Many studies have investigated the function of ATX-LPA signalling in tumour 
formation and metastasis since the discovery of ATX as the autocrine motility factor for 
melanoma cells.
17
 Subsequent experiments have identified the potential functions of 
overexpression of ATX in cancer progression, tumour cell invasion, and metastatic process, 
which involves the promotion of tumour angiogenesis in several malignant tumour tissues.
8, 19
 
High expression of ATX has been reported in different forms of tumours, including 
neuroblastoma, hepatocellular carcinoma, breast cancer, renal cell carcinoma, glioblastoma, lung 
cancer, B-cell lymphomas, and thyroid carcinoma.
17, 20
 Mechanisms regulating ATX expression 
are complicated and not fully understood. However, increasing evidence points to a critical 
function of ATX and LPA receptor signalling in cancer.
17
 Briefly, high expression levels of ATX 
and LPA receptors are found in a number of human malignancies. It has been reported in mouse 
models that overexpression of either ATX or LPA receptors stimulates metastasis and tumour 
formation, while knockdown has the reverse effect.  
Moreover, ATX mediates its effects via production of LPA; overexpression of ATX in 
cancers leads to elevated local levels of LPA.
4
 High LPA levels have been reported in the plasma 
and/or ascitic fluids of patients who have ovarian and pancreatic cancer, multiple myeloma, 
follicular lymphoma, and hepatocellular carcinoma. In particular, the serum levels of LPA are 
elevated by 90 % in patients with ovarian cancers when compared with normal physiological 
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levels.
20, 69
 Also, the ascitic fluids of patients with ovarian cancer have 10 times higher 
concentrations of LPA than healthy individuals. Furthermore, Yang et al.
28
 compared the 
expression of ATX level between both breast cancer and normal tissues, and they found a 
correlation between ATX expression and the invasiveness of breast cancer cells. Moreover, 
Baumforth et al.
70
 established that up-regulation of ATX elevated the formation of LPA, which 
led to improved viability and growth of Hodgkin lymphoma cells, whereas particular down-
regulation of ATX led to a decline in LPA levels, and thus, decreased cell survival and growth.  
In addition, overexpression of LPA receptors represents a significant function in 
carcinogenesis, invasiveness, potential of metastasis, and resistance of treatment in many kinds 
of tumours.
71
 Hama et al.
72
 demonstrated that LPA and ATX activate cell motility and migration 
in different cancer cell lines via the LPA1 receptor. Also, ATX expression facilitates bone 
metastasis via activation of LPA1 receptors in cancer cells and silencing of ATX expression 
decreases bone metastasis in these cells.
73
 Another study showed the effect of LPA on human 
colon cancer cells. Shida and collaborators also demonstrated that colon carcinoma cells highly 
expressed LPA1 but exhibited only low expression of LPA2 and no significant expression of 
LPA3.
74
 Also, it has found that LPA markedly increased the proliferation, migration and 
adhesion of colon cancer cells, which play a significant role in cancer progression and 
metastasis. On the other hand, LPA2 and LPA3 are highly expressed in most ovarian cancer 
cells.
75
 In thyroid cells, expression of LPA2 was elevated three fold in differentiated thyroid 
cancer in comparison with normal thyroid or goiter.
76
 
In summary, ATX plays significant roles in several human diseases, including cancer. 
High expression of ATX is found in a number of tumour cell types. Subsequent studies have 
shown that overexpression of ATX and LPA receptors has a significant function in cancer 
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progression, invasiveness, and metastasis. 
2.11 Drugs Targeting Autotaxin  
Because ATX has been linked to a number of human diseases, including cancer, obesity, 
diabetes, rheumatoid arthritis, multiple sclerosis, neuropathic pain, and Alzheimer’s disease,16 
ATX has become an attractive pharmaceutical target for developing new therapies. In particular, 
substantial progress has been carried out toward recognizing ATX as a clinical objective in the 
treatment of cancer.
16
 Therefore, the potential advantages of inhibiting ATX activity for human 
health have encouraged efforts by a number of research groups in academic institutions and 
pharmaceutical companies to determine and distinguish inhibitors of ATX enzyme activity. 
Different chemical categories of ATX inhibitors have been summarized in several review 
articles.
3, 4, 32
 
The first inhibition of the ATX enzyme was determined by using compounds that are 
known to chelate metals.
16
 L-histidine, the first compound showed to inhibit the 
lysophospholipase D activity of ATX,
4, 77
 inhibited ATX-stimulated migration of both human 
melanoma cells and ovarian carcinoma cells.  
2.11.1 Lipid and Lipid-Based Inhibitors of Autotaxin 
Many of the initial ATX inhibitors were lipid-like substrate or product analogues.
4, 78
 A 
number of analogues of LPA and S1P have been evaluated as ATX inhibitors. For example, a 
cyclic phosphatidic acid (cPA), a naturally occurring lipid bound to human serum albumin,
79
 is 
an analogue of LPA in which the sn-2 hydroxy group forms a 5-membered ring with the sn-3 
phosphate
80
 (Figure 2-6). An analogue of this compound, carba-cPA (Figure 2-7), was found to 
inhibit ATX activity without activating LPA receptors. It inhibited A2058 melanoma cell 
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invasion in vitro and B16F10 melanoma metastasis in vivo. However, this carba-cPA (ccpA) 
analogue seems to have further cellular targets, for example ccpA also inhibits LPA production 
by inhibiting RhoA activation.
81
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Cyclic Phosphatidic Acid (cPA) 
Figure 2-6: Chemical structure of cyclic phosphatidic acid (cPA). 
 
 
Figure 2-7: Chemical structure of carba analogue of cPA.
80
 
 
 
Moreover, FTY720, an approved drug for the treatment of relapsing multiple sclerosis,
82
 
is an analogue of S1P that has been shown to inhibit ATX activity in its phosphorylated form 
(FTY720-phosphate/FTY-P; Figure 2-8).
4, 32
 Van Meeteren et al.
83
 have been found that FTY-P 
is a competitive inhibitor of ATX in vitro and did not affect the activity of NPP 1, which is the 
closest relative of ATX. Once daily oral administration of FTY720 (3 mg/kg) in mice resulted in 
approximately a 50 % reduction of LPA levels in plasma.
4, 83
 These results suggest that FTY720 
might exhibit its anticancer effect by targeting ATX-LPA axis.  
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Figure 2-8: Chemical structure of FTY720-P.
4, 56
  
Another example are α-substituted methylene phosphonate analogues of LPA such as the 
α-bromophosphonate analogue of LPA (BrP-LPA).4, 16, 32 The anti-BrP-LPA (Figure 2-9) and its 
syn diastereomer exhibited activity at the LPA receptors and inhibited the lysoPLD activity of 
ATX, with the anti-isomer being more potent.
84
 Both isomers significantly reduced tumour 
volume in breast cancer xenograft models in vivo. However, the BrP-LPA displays high 
hydrophobicity, and it probably exhibits poor distribution across cell membranes.
16
 
 
Figure 2-9: Chemical structure of Anti-bromophosphonate analogue of LPA.
4, 16
 
 
In fact, many of the early ATX inhibitors were lipid analogues of LPA or other bioactive 
molecules and were showing potent inhibitory activity of ATX.
4
 However, The characteristics of 
this type of compounds limits their usage as potential lead compounds for drug development.
78
 
These analogues can act on the ATX enzyme and lead to stimulation of LPA or S1P receptors 
and initiation of the signalling cascades; therefore, they might have the opposite of their intended 
outcome.
43
 Both LPA and S1P analogues do not display only simple competitive inhibition of 
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ATX, although they exhibit mixed-type manner of inhibition, they might not interact merely with 
the active site.
85, 86
 Although a number of these analogues show potent inhibitory activity, such 
derivatives usually suffer from poor solubility and bioavailability due to the presence of a long 
lipophilic chain, limiting their use for in vivo applications.
4, 32
  
 
2.11.2 Non-Lipid Analogues as Autotaxin Inhibitors  
In more recent years, a number of small non-lipid inhibitors have shown more promise. 
Between these inhibitors, there are great structural differences in both the patent and academic 
literature, which has been reviewed elsewhere.
3, 4, 32
 Among them, a very important class of 
inhibitors was identified after screening a library of approximately 40,000 drug-like small 
molecules. A thiazolidinedione-based compound (IC50 2.5 μM) was identified as the most potent 
ATX inhibitor and was chosen as a lead for further chemical optimization.
4, 87
 The potency of the 
thiazolidinediones is increased dramatically by the introduction of a boronic acid moiety, which 
was designed to target the oxygen nucleophile of the catalytic Thr residue in ATX. The most 
potent analogue of these compounds was HA155 (IC50 6 nM; Figure 2-10), which is over 400 
times more potent against ATX than the initial screening hit. Also, the crystal structure of rat 
ATX in complex with the boronic acid inhibitor HA155 indicates that it forms a reversible 
covalent bond with the Thr209 nucleophile in the hydrophobic pocket of ATX.
4, 35, 88
 This 
compound supports the hypothesis that the boronic acid moiety targets the Thr oxygen 
nucleophile in the ATX active site (Scheme 2-3), whereas the hydrophobic 4-fluorobenzyl 
moiety of the inhibitor targets the hydrophobic pocket responsible for lipid binding. Thus, this 
finding indicates that ATX can be targeted by boronic acids and may also help the development 
of ATX inhibitors for therapeutic use.  
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Scheme 2-3: Hypothesized HA155 boronic acid binding to the active site of ATX. (Adapted from
87
) 
 
A number of piperidine and piperazine derivatives have also been discovered as ATX 
inhibitors.
4, 32
 The most potent ATX inhibitor among them was PF-8380 (Figure 2-10), which 
was developed by Pfizer researchers by screening a compound library followed by 
optimization.
89
 PF-8380 has an IC50 of 2.8 nM with moderate oral bioavailability ranging from 
43 %–83 %. PF-8380 caused more than a 95 % reduction of rat plasma LPA in vivo when it was 
orally administered at a dose of 30 mg/kg within three hours, suggesting that ATX is the main 
source of LPA during inflammation. Furthermore, at this dose, PF-8380 decreased inflammatory 
hyperalgesia with a similar efficacy as 30 mg/kg naproxen. Moreover, inhibition of ATX with 
PF-8380 resulted in reduced invasion and improved response to radiotherapy in glioblastoma cell 
lines,
90
 and pre-treatment of mice with PF-8380 before irradiation significantly delayed the 
progression of tumour growth in vivo.   
A virtual screening approach and docking experiments against an ATX catalytic domain 
homology model identified the pipemidic acid-based inhibitor H2L-7905958.
4, 32
 A number of 
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pipemidic acid derivatives based on this compound were designed, synthesized, and tested 
against ATX. These studies led to the discovery of an analogue of H2L-7905958 (Figure 2-10) 
with a meta-trifluoromethyl group that has two-fold greater potency (IC50 0.9 μM) than the lead 
compound.  
Bithionol (Figure 2-10) was determined to be an ATX inhibitor after screening of 960 
compounds from the GenPlus library.
4, 32
 Bithionol was able to reduce melanoma cell migration 
and invasion
91
 as well as produce a decline in tumour weight in a breast cancer carcinoma 
model.
16
 However, bithionol is highly hydrophobic and probably exhibits poor distribution 
across cell membranes.  
 
 
Figure 2-10: Examples of small molecule, non-lipid ATX inhibitors.
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To date, GLPG1690, developed by Galapagos, is the only ATX inhibitor that has been 
reported to proceed into clinical trials (Figure 2-11).
3
 GLPG1690 was shown to act as a potent 
inhibitor for both mouse and human ATX with IC50 =224 nM and IC50 =131 nM respectively. It 
has been found to reduce inflammation and displayed high efficacy in a model for chronic 
obstructive pulmonary disease (COPD).
3
 GLPG1690 has successfully completed Phase 1 trial 
and Galapagos is moving to explore Phase 2 clinical trials for Idiopathic pulmonary fibrosis 
(IPF).  
 
Figure 2-11: Chemical structure of GLPG1690.  
 
2.12 Structure Activity Relationship (Critical Features of Autotaxin Inhibitor) 
Initially, numerous LPC analogues were assessed to determine structure activity 
relationships of ATX substrates
86
 because LPC is the main substrate of ATX. Several structural 
features of LPC (Figure 2-12) were examined to display ATX preference for each modification, 
thus helping to define ATX substrate recognition. These features involved presence of a choline 
head group and a polar linker, length and degree of saturation of fatty acid side chain, acyl versus 
ether linking group of the hydrocarbon chain, and choline oxygen replacement by methylene and 
nitrogen.  
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Figure 2-12: Structural features of lysophosphatidylcholine, LPC.   
 
At the beginning, several LPC molecules were examined to investigate which 
hydrophobic chain length and degree of unsaturation is favorable for ATX. North et al.
86
 
compared LPC molecules that had 6:0, 8:0, 10:0, 12:0, 14:0, 16:0, 18:0, and 18:1 acyl chains. All 
of these molecules were evaluated at the same concentrations using the same conditioned media 
collected from a breast cancer cell culture. North et al.
86
 found that 14:0, 16:0, and 18:1 are the 
optimal substituent chain lengths for LPC compounds as ATX inhibitors. Also, regardless of the 
length of the hydrophobic chain, ATX shows a preference for an unsaturated tail, yet the location 
of unsaturation is not important.  
In addition, Nishimasu et al.
34
 determined the crystal structures of mouse ATX alone and 
in combination with LPAs that have different acyl-chain lengths and saturations (14:0, 16:0, 
18:1, 18:3, and 22:6). The phosphate group, glycerol moiety, and acyl-chain including C1–C12 
of LPA are distinguished by the protein in a similar manner in all complexes. One oxygen atom 
of the phosphate group combines with one Zn
2+ 
ion in the protein, whereas the other oxygen 
atom forms hydrogen bonds with the Asn230 side chain and the OH group and main-chain NH 
group of the Thr209 residue. The other oxygen atom of the phosphate moiety forms water-
mediated hydrogen bonds with Lys208, Asn230, and Asp473. These residues of ATX are highly 
preserved among the ENPP family enzymes, suggesting that the phosphate group of the 
substrates is recognized in a similar manner for the ENPP family members. Furthermore, all 
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ENPP family members, including ATX, revealed maximum activity at pH 8–9, indicating that 
deprotonation of the Zn
2+ 
coordinating residues is essential for the activity. The glycerol moiety 
of the LPA develops van der Waals interactions with both Thr209 and Leu243 residues, and it 
forms hydrogen bonds with both Asp311 and Glu308 and its OH group. Similarly, the acyl chain 
develops van der Waals interactions with Phe210, Leu213, and Tyr306 while it forms a hydrogen 
bond between its CO group and the OH group of Tyr306. 
In combination with ATX-14:0-LPA, the lipid chain is accommodated in the hydrophobic 
pocket lined by Ile167, Leu216, Ala217, Leu259, Phe273, Trp275, and Met512 residues.
34
 The 
overall structures of the free parts and the complexes are essentially similar, although alteration 
of a local conformation is detected in the active site. Notably, the side chains of Leu216 and 
Glu308 twist to accommodate LPA in these complexes. Similarly, in the ATX–16:0-LPA 
complex, the lipid chain is also accommodated in the hydrophobic pocket. However, when 
compared to the complex with 14:0-LPA, its electron density is relatively poor. Also, in the 
complex with 18:0-LPA, the electron density of LPA was not detected, which indicates that it is 
not bound to the ATX protein in a stable conformation. Therefore, the depth of the hydrophobic 
pocket is optimum for accommodating the 14:0-LPA lipid tail, and the logical length of the LPC 
chain of ATX is preferred as 14:0 > 16:0 >18:0. Regardless, in the ATX–18:0-LPA complex, the 
electron density was observed for LPA in the complexes with 18:1-LPA and 18:3-LPA. The acyl 
chain of these complexes turns at the unsaturated bonds (C9 = C10 for 18:1-LPA, and C12 = 
C13 and C15 = C16 for 18:3-LPA) and allows their lipid chain to be accommodated in the 
hydrophobic pocket. Therefore, these structures revealed that the existence of unsaturated bonds 
allows the long LPA compounds to be accommodated in the ATX active site consistent with the 
preference 18:3 > 18:1 > 18:0 for unsaturated bonds of LPC. Finally, in the ATX–22:6-LPA 
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complex, the longest LPA present in the plasma, the acyl chain turns at an unsaturated bond (C13 
= C14) and is lined in a U-shaped conformation in the active site without introducing the lipid 
tail into the base of the hydrophobic pocket. 
After estimating the optimum lengths of LPC chain, the impact of the choline functional 
group was tested. Both commercially available LPC (with choline head group) and LPA (lacks 
the choline group; Scheme 2-2) molecules with the same tail lengths, 16:0, 18:0, and 18:1, were 
identified to inhibit ATX.
86
 LPA and its structural analogues can be generalized as having a polar 
head group, a linkage group, and a hydrophobic chain (Figure 2-13).
92
 In all three cases, LPA 
showed better inhibition than corresponding LPC molecules. This result demonstrated that the 
presence of the choline head group could damage the recognition of ATX and may lead to 
destabilizing the substrate complex. 
 
Figure 2-13: Structural regions of LPA and its analogues.  
 
 Similarly, the effectiveness of ester versus ether linkages to the hydrocarbon chain was 
also evaluated by comparing both 16:0 and 18:0 of commercially available lysoPAF (with ether 
linker) compounds with LPC (with ester linker).
86
 As a result, no statistical difference was 
indicated for ATX inhibition between 16:0 lysoPAF and LPC, and 18:0 lysoPAF and LPC. Thus, 
the carbonyl functional group is not essential for ATX recognition. 
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Generally, activation of LPA receptors has been found to be dependent on the fatty acid 
species. In particular, unsaturated fatty acids of LPAs such as oleic acid (18:1), linoleic acid 
(18:2), or arachidonic acid (20:4) are more potent in stimulating the LPA receptor and enhancing 
biological activities than LPA with a saturated fatty acid.
8
 Similarly, other studies showed that 1-
oleoyl-LPA (18:1), 1-palmitoyl-LPA (16:0), and 1-myristoyl-LPA (14:0) increased the optimal 
inhibitory effect of LPA for ATX, whereas the LPA with shorter chain (6:0) had no significant 
effect.
43, 81
 This requirement of long acyl chains suggests that LPA and S1P directly interact with 
a hydrophobic pocket on the ATX enzyme. Therefore, this finding suggests that both LPA and 
S1P lipids act on the same regulatory site, and ATX is unable to distinguish between LPA and 
S1P as ligands. 
In summary, multiple structural features of LPC and LPA were assessed to determine 
structure activity relationships of ATX substrates, and the optimal unbranched chain lengths for 
ATX inhibitors are 14:0, 16:0, and 18:1. Also, ATX shows a preference for the unsaturated tail 
to allow the lipid chain to be accommodated in the hydrophobic pocket. The choline head group 
is not required for the recognition of ATX; further, there was no statistical difference between 
ester and ether linkages to the hydrocarbon chain. 
2.13 Enzyme Inhibition  
Enzymes have been an important target for therapeutic functions and drug design because 
of their essential function in biosynthetic pathways; enzyme inhibitors can inactivate a target 
enzyme or interfere with a specific metabolic pathway.
93
 Enzyme inhibitors may reversibly or 
irreversibly bind to a specific enzyme and inhibit that enzyme in different ways, both in vivo and 
in vitro.
94
 There have been a number of reversible ATX enzyme inhibitors reported; however, 
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there are only a limited number of irreversible inhibitors. Irreversible inhibition has an advantage 
over reversible inhibition; it is comparatively slower because it requires a chemical reaction 
between the inhibitor and enzyme. Additionally, eliminating or decreasing the concentration of 
enzyme inhibitors has no significant effect on inhibition activity and synthesis of new enzymes is 
required. Because we are looking for enzyme inhibitors as an anticancer treatment, irreversible 
inhibitors are preferred over reversible inhibitors.  
There are two main types of irreversible inhibition: nonspecific and specific irreversible 
inhibition.
94
 Nonspecific irreversible inhibition is a simple type of inhibition in which the 
inhibitor interacts in a direct way with one or more residues on the enzyme, leading to inhibition 
of the enzyme. This type of inhibitor is not specific to particular types of enzymes, yet it reacts 
with the side chains of amino acids that have the same reactions in many various enzymes and 
usually with various residues of the similar enzyme. With specific irreversible inhibition, a non-
covalently bound complex between an enzyme and an inhibitor is formed initially, followed by a 
subsequent reaction to form the irreversibly inhibited enzyme. Typically, the inhibitor binds the 
enzyme as a substrate, resulting in formation of an enzyme-substrate complex. Then, a reaction 
takes place within this complex, and finally, an irreversibly inhibited enzyme is produced.  
Two forms of specific irreversible inhibitors are known. The first type of inhibitors are 
usually known as active-site-directed inhibitors (ASDINS).
94
 Inhibitors of this type have a 
chemically reactive group attached to a substrate analogue. Within the enzyme-inhibitor 
complex, the high concentrations of those groups and residues on the enzyme surface will react 
together and result in irreversible inhibition. The second type of inhibitors is known as a 
mechanism-based inhibitor. An inhibitor of this type is not intrinsically reactive; rather, a non-
covalent complex is formed between the inhibitor and the enzyme specifically in the active site. 
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Formation of this bond is followed by a subsequent reaction within that complex that results in 
formation of a reactive species that reacts with the enzyme to form the irreversibly inhibited 
species. Furthermore, the inhibitor can exhibit a high extent of specificity to the target enzyme 
because the formation of the effective inhibitory species formed from the inactive compound 
includes the catalytic function of the enzyme itself. Also, the absence of the intrinsic reactivity 
reduces the possibility of undesirable reactions with other tissue constituents.  
Additionally, this type of enzyme activity can only be restored by adding more enzymes, 
but not by adding either products or inhibitors/substrates.
94
 This means that recovery from 
irreversible inhibition requires the synthesis of new enzyme to recover the inhibited enzyme. 
Generally, the turnover of the enzyme is a dynamic process, and the rate of new enzyme 
synthesis and removal of the inhibited one is balanced in the cell at any time. The rate of 
turnover of some enzymes in the liver can have significant implications for scheduling the 
dosage of irreversible inhibitors for therapeutic usage.
94
 Also, the turnover rates of the enzyme 
can be extremely varied in different tissues from different species. 
2.14 Irreversible Inhibitors of Autotaxin 
A number of reversible ATX enzyme inhibitors have been reported; however, there are 
only a limited number of irreversible inhibitors. Specifically, Parrill et al.
95
 successfully designed 
a novel class of compounds to inactivate ATX. Compounds such as mono- and di-
fluoromethylphenyl C12-C18 phosphodiesters are able to inhibit ATX
95
 (Figure 2-14). Inhibition 
occurs through a mechanism-based process that leads to the development of a reactive species 
that irreversibly inactivates the ATX enzyme. This reaction has two steps (Scheme 2-4). First, an 
active group Thr in the catalytic site of ATX attacks the phosphate group of the substrate, 
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leading to removal of fluoride ion and the formation of a reactive quinone methide (QM). In the 
second step, the QM reacts with an unknown nucleophilic amino acid side chain (such as lysine, 
arginine, histidine, aspartate, glutamate, serine, threonine, or cysteine). As a result, the active site 
is irreversibly modified. Therefore, the production of LPA from LPC, the natural substrate, is 
prevented. 
 
Figure 2-14: Structural formula of inventive compound.  
Where R is C12-18 alkyl or alkenyl; X is mono- or di fluoromethylphenyl (CH2F or CHF2); and it is in 
either the 2 or 4 position (ortho- or para-substitution). 
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Scheme 2-4: General reaction of inventive compound to inactivate ATX enzyme.
95
 
 
2.15 Autotaxin Degradation/Turnover 
Jansen et al.
96
 found that ATX is rapidly degraded and cleared from the circulation by the 
liver through first-pass metabolism. This rapid turnover was unexpected, suggesting that ATX is 
removed from circulation to a large extent by the liver. This finding is very important and has 
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significant implications for the development of ATX as an anti-tumour target.   
The circulating source and fate of ATX is significant information for examining ATX 
inhibitors in vivo as well as for the rational design of compounds that cause the reduction of 
ATX circulating levels.
96
 The Bollen laboratory has determined the fate of secreted ATX in 
healthy mice, and it found that the ATX is rapidly cleared from the circulation within minutes by 
the liver.
96
 The experiment showed that about 60 % of injected labeled ATX was maintained in 
the liver after five minutes, and about 20 % of labeled ATX could still be detected in the blood. 
Later, the liver-associated radioactivity continued to be reduced, and the amount of labeled ATX 
decreased after 24 hours. Correspondingly, there was an elevation of radioactivity in the intestine 
and urine. These results propose that the ATX enzyme is decomposed in the liver because ATX 
is too large to be filtered by the glomeruli of the kidneys. Indeed, these data strongly propose that 
the main site of ATX enzyme breakdown is the liver.  
In fact, this excessive turnover was surprising and suggests that the ATX enzyme is 
extensively removed from the circulation through the liver during first-pass metabolism, similar 
to some hormones such as insulin and glucagon.
96
 However, it has been suggested that the ATX 
enzyme is synthesized regularly at different places that still need to be determined because it can 
be immediately found in serum. The ATX enzyme is secreted by different cell types such as 
adipocytes,
10
 endothelial cells,
97
 and lymphocytes.
98
 Therefore, it has been hypothesized that the 
ATX enzyme is released by different types of cells in serum rather than being produced by one 
particular kind of tissue. However, the ATX enzyme is also expressed by the liver, indicating 
that at least part of its synthesis and decomposition is mediated by similar tissue. Additionally, 
Watanabe et al.
99
 have shown that there is an elevation in serum ATX concentration in 
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hepatectomized rats and rats with liver injury. This finding is consistent with the role of the liver 
in clearing ATX from the circulation.        
 
 
39 
CHAPTER 3: PURPOSE OF THE STUDY 
3.1 Significance of the Project  
ATX-mediated formation of LPA is associated with a number of disease states, including 
diabetes, obesity, Alzheimer’s disease, and various cancers.16 One particular interest of ours is 
the relationship between the ATX enzyme and cancer progression. Several studies have 
implicated the role of ATX–LPA signalling in cancer development and metastasis since the 
detection of ATX as the autocrine motility factor from melanoma cells. The potential functions 
of overexpression of ATX in cancer progression, tumour cell invasion, and metastatic processes 
involving promotion of tumour angiogenesis in several malignant tumour tissues have been 
frequently identified in subsequent experiments.
8, 19
 Because most LPA is produced by ATX 
activity, an inhibitor of the ATX catalytic site would block subsequent LPA signalling. In fact, 
inhibition of ATX has been established in vitro with numerous compounds that demonstrated 
promising in vivo anticancer properties.
16
 Therefore, this would provide an opportunity for 
introducing new cancer therapies.  
There is currently a need to design and synthesize novel, potent, and selective compounds 
that inhibit ATX. These compounds can provide significant information needed to understand 
the structural features critical to inhibit ATX for cancer treatment. Previous investigations have 
determined the importance of ATX-inhibiting compounds having an aryl phosphate or 
phosphonate moiety, which mimics the phosphate diester of LPC. A cyclic phenol phosphate 
group structurally mimics the previous aryl phosphate analogues, and it can be hydrolyzed to 
produce ortho-quinone methides (O-QM), which are highly reactive and electrophilic molecules 
known to modify biological nucleophiles
100
 (Scheme 3-1). We propose that inhibition will occur 
through a mechanism-based process that leads to development of a reactive quinone species that 
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irreversibly inactivates the ATX enzyme. This pro-drug strategy allows activation to a reactive 
intermediate that can afford further selectivity for the specific target. In this case, the activating 
enzyme is also the target for inhibition, potentially providing enhanced target selectivity. 
Because we are looking for enzyme inhibitors as an anticancer treatment, irreversible inhibitors 
are preferred over reversible inhibitors. 
Our research seeks to prepare and assess a series of cyclic phenol phosphate analogues 
for their ability to function as irreversible ATX inhibitors. Our research aims to investigate 
whether pro-drugs that form O-QM can have high selectivity as ATX inhibitors. The proposed 
cyclic phenol phosphates have not been previously prepared and can thus represent a new 
orientation for the study of ATX inhibitor analogues and may lead to the development of new 
treatments for ATX-related human diseases in the future, including cancer.  
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Scheme 3-1: ATX–mediated hydrolysis of cyclic phenol phosphate to O-QM. 
3.2 Hypothesis  
We hypothesize that cyclic phenol phosphate compounds will inactivate ATX enzyme via 
covalent modification due to formation of an O-QM mediated by enzyme activation. 
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3.3 Study objective  
The first step toward this goal is synthesizing a series of cyclic phenol phosphate compounds and 
testing them as irreversible ATX inhibitors. 
3.4 Specific Aims for the Objective 
To obtain our objective, we outlined the following aims: 
1. To synthesize acyl and alkyl ether derivatives of cyclic phenol phosphate compounds. 
2. To characterize these compounds by using different techniques such as nuclear magnetic 
resonance (NMR) and mass spectroscopy (MS). 
3. To detect the stability of these compounds. 
4. To determine the ability of these compounds to inactivate the ATX enzyme.  
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CHAPTER 4:  METHODOLOGY AND EXPERIMENTS 
4.1 Materials/Chemicals 
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO):                         
4-methoxy-1,3-benzenedimethanol, Boron tribromide (BBr3) solution (1.0 in methylene 
chloride), anhydrous Dichloromethane (DCM), Acetic anhydride (Ac2O), 4-(dimethylamine) 
pyridine (DMAP), Triethylamine (TEA), Methanol-D4, Deuterium oxide, tert-Butyldimethylsilyl 
chloride (TBDMSCl), Imidazole, 2-hydroxy-5-methoxybenzaldehyde, Phosphorus (V) 
oxychloride (POCl3),  Dimethyl sulfoxide (DMSO), Salicylaldehyde, 2,5-
dihydroxybenzaldehyde, 2,2-dimethoxypropane, p-Toluenesulfonic acid (pTsOH), 
Tetraethylammonium fluoride, 1-bromotetradecane, and Hydrogen chloride (HCL) solution 
4.0 M in dioxane. Ethyl acetate (EtOAc), Petroleum Ether (PE), DCM, Chloroform, Methanol 
(MeOH), Ethanol (EtOH), Hexane (Hex), Hydrochloric acid (HCl), Magnesium sulfate 
(MgSO4), Potassium carbonate (K2CO3), Sodium borohydride (NaBH4), Celite™ 545 Filter aid 
and sea sand used in the flash columns were obtained from Fisher Scientific (Fairlawn, NJ). 
Chloroform-D and Dimethyl sulfoxide-D6 were obtained from Cambridge Isotope Laboratories 
Inc. (Andover, MA). Potassium hydroxide (KOH) was obtained from BDH Chemicals (Toronto). 
Sodium bicarbonate (NaHCO3) and silica gel 60 (0.040-0.063 mm) used in flash columns were 
obtained from EMD Chemicals Inc. (Gibbstown, NJ). Benzyl bromide and Tetrahydrofuran 
(THF) extra dry was obtained from ACROS. Formic acid was obtained from EASTMAN 
KODAK CO. Tris Hydrochloride was obtained from EM science. Perchloric acid was obtained 
from GFS Chemical CO. HPLC runs were done with HPLC grade water and acetonitrile that 
were obtained from Fisher Scientific (Fairlawn, NJ). 
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4.2 Equipments/Instrumentation 
 TLC aluminium sheets were coated with silica gel 60 F254 purchased from Merck. 
Rotary evaporator systems consisted of Büchi heating bath B-490, Büchi Rotavapor R-200, and 
Büchi v700 vacuum pump with attached v850 vacuum controller. Samples in test tubes were 
concentrated using Eppendorf Concentrator 5301 with Büchi Vac V-700 with attached v850 
vacuum controllers. Trace amounts of solvent and moisture were removed using a Trivac High 
Vacuum Pump. Vortexed reactions utilized a VWR Scientific Products mini vortexer. Water was 
purified with a Millipore Milli-Q system with a Quantum TEX Cartridge (Mississauga, ON). 
Incubations took place in a Boekel Grant ORS 200 shaking heating water bath, Freeze drier from 
Labconco. The pH adjusted by pH meter from VWR Scientific Products. High Performance 
Liquid Chromatography-Ultraviolet system consisted of an Agilent Series 1200 quaternary pump 
(G1311A) with online degasser (G1322A), autosampler (G1329A) and photodiode array detector 
(G1315D) (Agilent Technologies, Mississauga, ON). Analytical column was a 150 × 3 mm 
Hypersil GOLD phenyl, 5 µ particle size column (Thermo scientific). The HPLC system was 
controlled by, and data was processed using ChemStation software (Agilent Technologies, 
Mississauga, ON). NMR experiments were performed on a Bruker AVANCE DPX-500 
spectrometer, and data processed by TopSpin 3.2 software. All compounds were drawn and 
named using ACD/ChemSketch. MS experiments were conducted using AB SCIEX 4000 
QTRAP (AB SCIEX instruments) quadrupole linear ion trap mass spectrometer coupled to an 
Agilent 1100 system consisting of an Agilent 1100 G1311A pump and an Agilent 1100 G1329A 
autosampler (Agilent Technologies, Mississauga, ON). Data acquisition and analysis was 
performed using Analyst 1.5.1 software from AB SCIEX. Docking experiments were performed 
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on Molecular Operating Environment (MOE) software (2014.09) from the Chemical Computing 
Group. 
4.3 Specific Aim 1 
4.3.1 Synthesis of Acyl Derivatives of Cyclic Phenol Phosphate Analogues 
We have proposed that cyclic phenol phosphate analogues will be prepared by 
modification of an existing synthetic strategy utilized in the preparation of vitamin B6 
analogues.
101
 Synthesis of the acyl analogues requires several steps that will provide a general 
route to this group of analogues (Scheme 4-1). These steps involve deprotection of an alcohol 
group of a commercially available starting material, followed by protection of the alcohol 
groups, addition of phosphoryl chloride, cyclization of the phosphate mediated by a base, and 
esterification using acyl chloride with different side chains (C14, C16, and C18).  
 
 
 
45 
 
Scheme 4-1: Proposed synthetic scheme for the preparation of acyl derivatives. Where R is (C14, 16,18) 
 
4.3.1.1 Demethylation Step
102, 103
 
The first step for synthesis of acyl derivatives of cyclic phenol phosphate analogues is the 
demethylation step. Under a nitrogen atmosphere, compound 1 (4-methoxy-1,3-
bezenedimethanol) was dissolved in anhydrous CH2Cl2 and the solution was cooled either to -78 
°C or 0 °C. BBr3 (1 M solution in CH2Cl2) was added to the cooled solution carefully via a 
syringe, and the mixture was stirred for two hours. After warming to room temperature (RT), 
water was added to quench the reaction, and the solution was extracted with DCM. The 
combined organic layers were washed with 10 % sodium bicarbonate, 1 M HCl, and water. The 
resulting solution was dried over magnesium sulfate. After filtration, the solvent was removed 
under vacuum and purified by flash column chromatography over silica (2:1 EtOAc\PE).  
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4.3.2 Synthesis of Alkyl Ether Derivatives of Cyclic Phenol Phosphate Analogues 
We have proposed that a different starting material than the one shown in Scheme 4-1 for 
the acyl analogues is required to synthesize the alkyl ether analogues (Scheme 4-2). This process 
involves selective methylation of the hydroxyl group, followed by introduction of the alkyl ether 
moiety. Next, deprotection of the alcohol group will be carried out before introducing the 
phosphate group in a similar manner to the acyl derivatives. The length of the carbon side chain 
(R) will vary from fourteen to eighteen carbons in length (C14, C16, and C18), even though a 
shorter chain will be prepared to estimate solubility in the determination of aqueous stability. 
Alkyl bromides will be purchased where available. 
All compounds will be analyzed and identified by techniques including, nuclear magnetic 
resonance (NMR) and mass spectroscopy (MS).  
 
Scheme 4-2: Proposed synthetic scheme for the preparation of alkyl ether derivatives. Where R is (C14, 
16,18) 
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4.4 Specific Aim 2  
We will verify the stability of the cyclic phenol phosphate compounds in aqueous 
solution. The synthesized compounds (0.1 mM) will be incubated in 50 mM TRIS buffer pH 8.0 
at 37 °C.
104
 Reversed-phase high performance liquid chromatography (RP-HPLC) will be used to 
determine any loss of starting material and forming of decomposition products.
105
 The 
identification of decomposition products will be determined through HPLC and NMR. We will 
also determine the stability of the shorter chain analogues. If stability is pH dependent, the 
stability of the longer chain analogues will be determined at the pH where the stability is 
observed. In addition, solubility of the longer chain analogues will be determined by dilution in 
50 mM TRIS buffer (pH 8). 
4.4.1 Stability Study Determination 
The synthesized compounds in DMSO (50 mM) and internal standard (KA-1-09-2; 
Figure 4-1) in ACN (50 mM) were added to TRIS buffer (50 mM, pH 8.0) and vortexed for 5 
seconds to give final concentrations of 0.1 mM each. The mixture was incubated in sealed 
containers at 37 °C in the Boekel Grant ORS 200 shaking heating water bath for 5 minute. 
Aliquots (300 µl) were taken at various time intervals (0 h, 3 h, and 6 h), and samples were 
analyzed directly by HPLC. Test compounds were verified by the elution time of standards and 
quantitated by their corresponding standard curves. All eluates were monitored by photodiode 
array detection, and runs were monitored at 280 nm. Peak areas were calculated and product 
reported as the ratio of the area of compound/internal standard. The experiment was run in 
triplicate and the data are reported as the mean ± standard error.  
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O
CH3
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Figure 4-1: Structure of KA-1-09-2 used as the internal standard. 
 
4.4.2 High Performance Liquid Chromatography Analyses  
A reverse phase high performance liquid chromatography (RP-HPLC) method was 
developed to determine purity of the prepared analogues and any loss of starting material and 
forming of decomposition products. The internal standard was run alongside for comparison 
(KA-1-09-2; Figure 4-1). The RP-HPLC method employed a 150 × 3 mm Hypersil GOLD 
phenyl, 5 µ particle size column (Thermo scientific) at a flow rate of 1 ml/min using gradient 
elution. Solvent A consisted of water with 0.1 % formic acid, and Solvent B was acetonitrile 
containing 0.1 % formic acid. The HPLC grade acetonitrile and formic acid were filtered through 
a 0.45 micron filter, whereas Millipore water was used without further purification. Both 
solvents were sonicated and degassed prior to use. A gradient of 85 % A for 2 min, decreased to 
15 % A over 5 min, held isocratic for 1 min, returned to 85 % A in 2 min, and held isocratic for 3 
min. The HPLC gradient outlined in Table 4.1 was used to detect and separate compounds. All 
eluates were monitored by photodiode array detection at 280 nm. 
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Table 4-1: HPLC gradient program employed for the separation of analogues. 
Time (min) % Solvent A
* 
% Solvent B
**
 Flow rate (mL/min) 
2.00 85 15 1.00 
7.00 15 85 1.00 
8.00 15 85 1.00 
10.00 85 15 1.00 
13.00 85 15 1.00 
A* water with 0.1 % formic acid 
B** acetonitrile with 0.1 % formic acid 
 
4.5 Specific Aim 3  
To determine the ability of the cyclic phenol phosphate compounds to inactivate ATX 
enzyme, ATX inhibition assays will be carried out as described earlier by our colleagues at the 
University of Memphis.
54, 78, 86
  
4.5.1 Autotaxin Inactivation Analysis 
The effectiveness of these analogues will be determined by estimating ATX-mediated 
hydrolysis of the synthetic LPC analogue FS-3 at certain excitation and emission wavelengths 
resulting from cleavage of FS-3 by ATX.
95
 Briefly, the test protocol will be as follows: ATX 
inhibition will be determined by using the synthetic substrate FS-3 (Echelon Biosciences, Inc., 
Salt Lake City, Utah, USA) and concentrated conditioned serum-free medium (CCM) from 
MDA MB-435 cells as the source of ATX in an assay buffer of (1mM MgCl2, 1mM CaCl2, 5mM 
KCl, 140mM NaCl, 50mM Tris, pH 8.0). The assay will be performed in 96 well plates in a 
Synergy-2 plate reader (BioTek, Winooski, Vt.) using LPA as a control. The fluorescence will be 
measured at excitation and emission wavelengths of 485 and 538 nm, respectively, after 
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incubation at 37 °C. The data will be normalized to the vehicle control and mean ± standard 
deviation of triplicated wells will be expressed as a percentage of ATX activity.   
4.6 In Silico Docking Studies with Autotaxin  
Docking, a computer simulation modeling the interaction between a receptor active site 
and a ligand, is a significant tool in structure-based drug design.
44
 The technique of docking 
depends on positioning the ligand in various conformations and orientations within the binding 
site in order to determine optimum binding geometries and energies. Herein, we performed the 
docking study by using Molecular Operating Environment (MOE) software from the Chemical 
Computing Group for docking some compounds into ATX. The MOE searches for favorable 
binding conformations between the ligand and a molecular target, which is usually a protein.
44
 
Several conformations called “poses” are produced and scored for each ligand. Typically, 
scoring function indicates favorable hydrophobic, ionic, and hydrogen bond contacts. For good 
results of docking, low scores must be assigned to good poses.  
The crystal structure of mouse ATX with PDB ID: 3NKM and 2.0 Å Resolution was 
chosen for the docking study. Active site 1 containing the key residue Thr209 was isolated for 
this docking study (Figure 4-2). A number of ligands were docked to the active site of the ATX 
enzyme to assess their binding affinity. Ligands consist of (a) LPA with different long side 
chains (14:0, 16:0, and 18:0) as standard; (b) our synthesized analogues A1 and A2; (c) the 
proposed alkyl ether derivatives of cyclic phenol phosphate analogues with different long side 
chains (C14, C16, and C18); (d) the proposed acyl derivatives of cyclic phenol phosphate 
analogues (C14, C16, and C18); and (e) the mono-fluorophosphodiesters (C14, C16, C18) compounds 
synthesized by our collaborators as ATX irreversible inhibitors. 
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Figure 4-2: The structure of free active site 1 of ATX enzyme (PDB ID: 3NKM at 2.0 Å Resolution). 
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CHAPTER 5: RESULTS AND DISCUSSION 
 
In order to meet our objective of evaluating cyclic phenol phosphates as ATX inhibitors 
in vitro, we first needed to prepare the novel cyclic compounds. Due to the simple chemical 
structure of LPA and its effects in cancer, it has attracted the attention of the cancer therapeutics 
field, and initial studies on the development of therapeutics have typically been based on the 
LPA scaffold.
71
 Therefore, we designed our compounds to mimic LPA-based inhibitors of 
ATX.
4, 32, 33, 56
 Previous studies on ATX inhibitors have suggested that the linker between the 
aromatic ring and the alkyl chain can be either an acyl or an alkyl ether, and the optimal 
unbranched chain lengths for ATX inhibitors are 14:0, 16:0, and 18:1.
86
 Thus, we proposed two 
synthetic methodologies that can yield cyclic phenol phosphates with either an acyl (Scheme 4-
1) and an alkyl ether linkage (Scheme 4-2). The proposed synthetic analogues of three acyl and 
three alkyl ether derivatives of cyclic phenol phosphate with side chains of different lengths (C14, 
C16, and C18) are shown in Figure 5-1 and Figure 5-2, respectively. They have been proposed for 
the purpose of studying their ability to inhibit ATX. 
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Figure 5-1: Proposed synthetic analogues of acyl cyclic phenol phosphate. 
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Figure 5-2: Proposed synthetic analogues of alky ether cyclic phenol phosphate.  
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 Different starting materials are required for the two approaches, as outlined in Scheme 4-
1 and Scheme 4-2. Our strategy was to develop methods that would allow us to easily 
incorporate different substituents on our cyclic phosphate scaffold and thereby provide a route to 
explore structure-activity effects of the side chain. All of the reactions performed in the synthesis 
of the cyclic phenol phosphates analogues described herein were carried out several times.  
5.1 Attempted Synthesis of Acyl Derivatives of Cyclic Phenol Phosphate 
Analogues 
5.1.1 Demethylation Reaction 
The commercially available compound 1 (4-methoxy-1,3-bezenedimethanol) was used as 
the starting material for synthesis of acyl derivatives of cyclic phenol phosphates. The strategy 
we employed for synthesis of acyl derivatives of cyclic phenol phosphates was to convert the 
methoxy group into a hydroxyl group by dealkylation, which would then allow for construction 
of the cyclic phosphate portion of the analogue and provide an easy route to multiple acyl 
derivatives (Scheme 4-1). The O-dealkylation of ethers remains a basic functional group 
conversion, mainly as a deprotection method to unmask the hydroxyl group.
106
 We utilized BBr3, 
a Lewis acid, which is a potent reagent for dealkylation of ethers and is well known for 
deprotecting methyl aryl ethers.
107, 108
 Consequently, we attempted demethylation of the methyl 
group at position C4 of the aromatic ring of compound 1 using BBr3. The mechanism of action 
of BBr3 for the O-demethylation step is shown in Scheme 5-1. The reaction proceeds via 
formation of a complex between the boron of the reagent and the ether oxygen atom.
108
 The alkyl 
aryl ether then cleaves at the alkyl oxygen bond, resulting in ArOH and alkyl bromide.  
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Scheme 5-1: Mechanism of Action of BBr3 for O-demethylation.
108
 
 
Our initial attempt at demethylation (1:1 BBr3/1 (CH2Cl2), -78 
o
C) was unsuccessful, 
resulting in only starting materials (Scheme 5-2). We hypothesized that the alcohol groups 
interfered with the demethylation, possibly by complexation of the BBr3, as shown in Figure 5-3. 
Loman et al.
109
 found that problems are encountered and poor yields are obtained with attempts 
to demethylate nonadjacent methoxy groups or on one aromatic ring, and when a stable chelate is 
formed. Subsequent attempts with increased ratios of BBr3 were similarly unsuccessful, although 
these reactions produced a mixture of unidentified products. To more fully explore this issue, we 
repeated the demethylation step under increased temperature, different reaction times, and 
different ratios of starting materials to BBr3 as shown in Table 5-1. None of these reactions 
yielded the expected product. In an effort to overcome this issue, we decided that the two 
hydroxyl groups of 1 should be masked by different protecting groups prior to the dealkylation 
step. 
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Scheme 5-2: Unsuccessful attempts of demethylation of compound 1. 
Reagents and Conditions: i) BBr3/DCM, -78 ᴼC or 0 ᴼC. 
 
 
 
Figure 5-3: Potential BBr3–starting material interactions.  
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Table 5-1: Demethylation of different compounds under various conditions. 
 
Compound 
no. 
Mole 
Comp: BBr3 
Time 
(h) 
Starting Temp 
(ᴼC) 
Result 
1 1:1 2 -78 
NMR showed no change in starting 
material 
1 1:1 1 -78 No change in starting material 
1 1: 2.5 2 -78 NMR showed unidentified products 
1 1: 3.5 2 -78 NMR showed unidentified products 
1 1: 3.5 0.5 0 
NMR and MS showed unidentified 
products 
1 1:4 2 0 NMR showed unidentified products 
1 1:5 1 0 NMR showed unidentified products 
2 1: 2.5 2 -78 NMR showed unidentified products 
2 1: 2.5 2, 7, 20 -78 NMR showed unidentified products 
2 1: 3.5 2 -78 NMR showed unidentified products 
2 1: 3.5 2 0 NMR showed unidentified products 
3 1: 3.5 2, 4 0 NMR showed unidentified products 
4 1:5 4 0 NMR showed unidentified products 
4 1:5 1.5 0 NMR showed unidentified products 
4 1:10 2 0 NMR showed unidentified products 
 
5.1.2 Acetyl Protection
110    
 
Protection of the two hydroxyl groups of compound 1 via acetylation was performed.  
Acetylation with Ac2O, DMAP, and TEA at RT afforded an acetylated compound 2 as yellow oil 
(83.74 %) (Scheme 5-3). The product was analyzed using NMR techniques, and the NMR 
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spectrum of protected compound 2 is shown in Figure 5-4. However, the demethylation of the 
compound 2 with different ratios of BBr3 at low temperature (Table 5-1) gave unidentified 
products, as shown in Figure 5-5.   
 
Scheme 5-3: Demethylation of compound 1 after protection with different groups.   
Reagents and Conditions:  i) Ac2O, DMAP, TEA, RT, 83 %; ii) BBr3/DCM, -78 ᴼC or 0 ᴼC; iii) benzyl 
bromide, KOH, THF, RT, 53 %; iv) TBDMSCl, imidazole, DCM, RT, 53 %.                    
 2: 
1
H NMR (500 MHz, D2O): δ (ppm) 2.07 (3H, s); 2.11 (3H, s); 3.84 (3H, s); 5.04 (2H, s); 5.15 (2H, s); 
6.87 (1H, d, J = 8.2 Hz); 7.33 (2H, m).                                                                               
3: 
1
H NMR (500 MHz, D2O): δ (ppm) 3.87 (3H, s); 4.56 (1H, s); 4.58 (1H, s); 4.66 (4H, d, J = 4.4); 6.90 
(1H, d, J = 8.4); 7.33 (3H, m); 7.40 (8H, m); 7.48 (1H, d, J = 2.1 Hz).                          
 4: 
1
H NMR (500 MHz, D2O): δ (ppm) 0.13 (6H, s); 0.15 (6H, s); 0.97 (9H, s); 0.99 (9H, s); 3.84 (3H, s); 
7.73 (2H, s); 4.79 (2H, s); 6.81 (1H, d, J = 8.5 Hz); 7.19, 7.21 (1H, dd, J = 2.1 Hz); 7.48 (1H, s). 
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Figure 5-4: 
1
H NMR data of compound 2 in CDCl3. 
Figure 5-5: Sample of 
1
H NMR data for attempted demethylation of compound 2. 
Although protection of the starting material, compound 1, with an acetyl group was 
successful, the demethylation reaction after the acetylation was unsuccessful. It is possible that 
the reaction did not occur at the required position. This failure of the reaction could be due to 
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several reasons. One possibility may be that the BBr3 reacted with other oxygen atoms (*) 
instead of the ether oxygen, which may lead to the loss of the acetate group during hydrolysis 
(Scheme 5-4).  Alternatively the boron complex is formed and the bromide ion attacks one of the 
benzyl carbons with loss of acetate, and we think this mechanism is more likely in this case. 
 
Scheme 5-4: Potential interaction of BBr3 with compound 2.  
Another reason may be due to the electron-withdrawing effect of the acetate group. 
Therefore, both acetate groups may pull electron density toward them, which may have an effect 
on the whole reaction because they decrease the nucleophilicity of the methoxy O-atom. We 
believe that the electron-withdrawing effect of the acetates is likely responsible as they would be 
too electrophilic to react with BBr3.  
5.1.3 Benzyl Protection
111
  
A second protecting group was chosen to avoid the potential Lewis acid catalyzed 
protecting group hydrolysis. The two hydroxyl groups of 1 were protected via benzylation. 
Compound 1 was benzylated using benzyl bromide and KOH in THF at RT to give compound 3 
as a yellowish oil (53.05 %), and Figure 5-6 shows the NMR spectrum of 3. Attempts at 
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demethylation of compound 3 also did not result in the anticipated product, (Scheme 5-3) despite 
altering the temperature and ratio of BBr3 to 3 (Table 5-1), as shown in NMR (Figure 5-7). 
 
Figure 5-6: 
1
H NMR data of compound 3 in CDCl3. 
Figure 5-7: Sample 
1
H NMR data for attempted demethylation of compound 3. 
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Although benzyl protection of the starting material, compound 1, was successful, the 
dealkylation reaction after the benzylation was again unsuccessful. This failure of the reaction 
could be due to several possibilities. First, it could be due to the BBr3 interacting with other 
oxygen atoms (*) instead of the ether oxygen (Scheme 5-5). Multiple ether oxygen atoms are 
present as well as multiple benzyl CH2 positions, any of which may undergo dealkylation, 
leading to a mixture of products, as outlined in Scheme 5-5. It may simply be that under our 
conditions there was insufficient selectivity for reaction of BBr3 with the desired site.  
 
 
Scheme 5-5: Potential interaction of BBr3 with compound 3.  
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5.1.4 Silyl Protection
112
   
It is possible that the electron-withdrawing effect of the benzyl or the acetyl groups in our 
previous attempts at demethylation might have contributed to the poor outcome, we decided to 
try using an electron-donating protecting group. Compound 1 was treated with tert-
butyldimethylsilyl chloride (TBDMSCl) and imidazole in DCM at RT, which gave compound 4 
as a colorless oil (53.85 %). The product was analyzed using NMR techniques, and the 
1
H NMR 
spectrum of protected compound 4 is shown in Figure 5-8. Again the demethylation of 
compound 4 with different BBr3 ratios at different times (Table 5-1), after protection of the two 
hydroxyl groups with the tert-butyldimethylsilyl (TBDMS) group, did not afford the expected 
product (Scheme 5-3), as shown in NMR (Figure 5-9).  
Figure 5-8: 
1
H NMR data of compound 4 in CDCl3. 
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Figure 5-9: Sample of 
1
H NMR data for attempted demethylation of compound 4 in CDCl3. 
Our last attempt at this strategy was the incorporation of an electron-donating TBDMS 
protecting group. As in the previous approaches, we were able to successfully protect the alcohol 
groups, but the demethylation reaction was once again unsuccessful. This failure might be due to 
the BBr3 reacting with other oxygen atoms (*) instead of the ether oxygen (Scheme 5-6). Since 
the TBDMS is an electron-donating group, the increased electron density at the benzyl oxygens 
may increase their reactivity with BBr3. 
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Scheme 5-6: Potential interaction of BBr3 with compound 4. 
 
5.1.5 Attempted Demethylation Reaction Under Various Conditions 
Because protecting groups having an effect on demethylation reactions, we also decided 
to investigate other features of the demethylation reaction, such as solvent, reactant ratios, and 
temperature that will be discussed in more detail further on. 
5.1.5.1 Solvent 
DCM is frequently used as a solvent for the demethylation reaction. As Sharghi et al.
113
 
have shown using BBr3 for demethylation at low temperature in DCM produced a high-
percentage yield. By protecting compound 1 with different protecting groups (acetyl, benzyl, and 
silyl), all of the protected compounds 2, 3, and 4 become more lipid soluble. Therefore, solubility 
in the DCM should not be an issue, and we observed no solubility problems. 
5.1.5.2 Ratio   
It is recommended to utilize one equivalent of BBr3 for each ether group to be 
dealkylated; however, low yields have been reported in some cases.
108
 Thus, we tried different 
O
CH3
O
Si
O
Si* *
BBr3
O
CH3
O
Si
O
+
Si
B
Br Br
Br
-
O
CH3
O
Si
Br Br2B
O
Si+ OH Si
H2O
4
 
 
66 
ratios of the dealkylating reagent, starting with one equivalent of BBr3 and then gradually 
increasing the amount of the reagent to make sure that we had a sufficient excess of BBr3. As 
Table 5-1 shows, the 1:1 ratio resulted in no change, so clearly an excess of BBr3 was necessary. 
However, using more BBr3 resulted in multiple reactions occurring. Thus, it solves the problem 
of no reaction occurring, but it creates a different problem: multiple reaction products. 
5.1.5.3 Temperature 
McOmie et al.
108
 showed that BBr3 is a potent and selective reagent for demethylation of 
aryl methyl ethers, and aromatic ethers can be cleaved by BBr3 at low temperature. Because the 
BBr3 dealkylation reactions are highly exothermic, low temperatures are typically used.
107
 
Therefore, we performed the dealkylation reactions using BBr3 under different low temperatures, 
as shown in Table 5-1, to try to make the reaction selective and to obtain a good yield.  
Overall, for the synthesis of acyl derivatives of cyclic phenol phosphate analogues, the 
dealkylation reactions were unsuccessful either directly or after protection with different groups, 
although we used a variety of dealkylating reagent amounts and temperatures. We are uncertain 
why this reaction did not work, but it is probably because there are many competing reaction 
sites, so we either obtained too little or no desired product. Therefore, we conclude that one or 
more structural feature(s) of compound 1 prevent the demethylation reaction from occurring. 
Obviously, the proposed synthetic demethylation step proved practically challenging, as the 
expected products were not obtained.  
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5.2 Attempted Synthesis of Alkyl Ether Derivatives of Cyclic Phenol 
Phosphate Analogues 
 
Because attempts at demethylation of 1 were unsuccessful, we turned our attention to the 
second approach, which is to synthesize alkyl ether derivatives of cyclic phenol phosphate 
analogues. We proposed a synthetic pathway that involves selective methylation of the hydroxyl 
group, followed by introduction of the alkyl ether moiety (Scheme 4-2). Next, deprotection of 
the alcohol group will be carried out before introducing the phosphate group in a similar manner 
to the acyl derivatives. The length of the carbon side chain (R) will vary from fourteen to 
eighteen carbons in length, even though a shorter chain will be prepared as a model reaction for 
the determination of aqueous stability.  
However, the proposed synthetic pathway (Scheme 4-2) of preparation of alkyl ether 
derivatives was modified to avoid the demethylation step in this pathway (due to our previous 
experience) and to determine that a cyclization with POCl3 could be carried out to obtain our 
proposed analogues (Figure 5-2). Therefore, we proposed a modified synthetic pathway that 
focused on constructing the active portion of our analogues, the cyclic phenol phosphate group, 
without the long side chains that will be shown in more detail further on (Section 5.2.1). 
5.2.1 Pathway 1: Cyclic Phenol Phosphate Analogues without Long Side Chain 
The starting materials for our second approach were commercially available: compound 5 
(Salicylaldehyde) and compound 6 (2-hydroxy-5-methoxybenzaldehyde). Notably, these 
compounds provide the advantage of shortening the proposed synthetic step by three reactions 
(Scheme 5-7). A reduction of both compound 5 and 6 separately with NaBH4 in MeOH at RT 
produced compound 7 (the alcohol) as white crystals (56.09 %) and 8 as yellowish white crystals 
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(53.19 %) respectively (Scheme 5-7). The addition and intramolecular cyclization of the 
phosphate group was carried out through treatment of the alcohol with a base (TEA) in THF at -
70 ᴼC, followed by the addition of POCl3.
114
 The reaction mixture was brought to room 
temperature in stages: to -40 ᴼC for one hour, and then to RT overnight. Then, the crude mixture 
was filtered, concentrated under vacuum, and purified by flash column chromatography over 
silica (1:1 Hex/EtOAc). The product was shaken with water and dried to yield analogue 1 (A1) 
as white crystals (52.06 %) and analogue 2 (A2) as beige crystals (67.51 %), respectively 
(Scheme 5-7). This pathway successfully produced A1, unsubstituted cyclic phenol phosphate 
(Figure 5-10), and A2, methoxy-substituted cyclic phenol phosphate (Figure 5-11).  
 
Scheme 5-7:  Synthetic pathway for preparation of cyclic phenol phosphate with no chain (A1) or with 
short side chain (A2). 
Reagents and Conditions:  i) NaBH4, MeOH, RT; ii) POCl3, THF, TEA, −70 °C, 1 h, −40 °C, 1 h, RT, 
overnight. 
A1: 
1
H NMR (500 MHz, D2O): δ (ppm) 5.14, 5.16 (1H, s); 6.89 (1H, d, J = 8.4 Hz); 7.00 (1H, m); 7.06 
(1H, d, J = 6.3 Hz); 7.21 (1H, m). 
31
P-NMR (202 MHz, D2O): δ (ppm) -5.97. 
13
C NMR (125 MHz, D2O): 
δ (ppm) 67.00, 118.30, 121.60, 123.07, 125.49, 129.09, 150.62. ESI-MS (m/z) = 187.1 [M+H]+  
A2: 
1
H NMR (500 MHz, D2O): δ (ppm) 3.67 (3H, s); 5.10, 512 (1H, s); 6.66 (1H, d, J = 2.8 Hz); 6.79 
(1H, dd, J = 2.8 Hz, J = 9.0 Hz); 6.85 (1H, d, J = 9.0 Hz). 
31
P-NMR: (202 MHz, D2O): δ (ppm) -5.82.                                                 
13
C NMR (125 MHz, D2O): δ (ppm) 55.73, 66.93, 110.27, 114.78, 119.22, 122.37, 144.75, 154.25. ESI-
MS (m/z) = 217.2 [M+H]
+
 
 
 
Figure 5-10: Molecular structure of unsubstituted alkyl ether of cyclic phenol phosphate analogue 1 (A1) 
with Molecular Formula (C7H7O4P) and Molecular Weight (186.101842).  
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Figure 5-11: Molecular structure of methoxy substituted alkyl ether of cyclic phenol phosphate analogue 
2 (A2) with Molecular Formula (C8H9O5P) and Molecular Weight (216.127822).  
 
5.2.2 Pathway 2: Cyclic Phenol Phosphate Analogues with Long Side Chains 
The previous pathway successfully provided us with two analogues: A1 (without a side 
chain) and A2 (with only a methoxy group side chain). This method served as a model reaction 
to confirm that we could install the cyclic phosphate moiety in the presence of an alkyl ether 
functional group. We then set our sights on preparing the phenol/alcohol starting material with 
long chain alkyl ether. Thus, for preparation of alkyl ether derivatives of the cyclic phenol 
phosphate with long side chains (C14, C16, and C18), a different synthetic pathway was proposed 
and adapted from the literature
112
 in order to introduce the long side chain first, and then carry 
out the cyclization to obtain the corresponding analogues (Scheme 5-8). Most of this pathway 
was done in cooperation with a summer student (Sarah Petriew). 
A benefit to the proposed procedure for preparing the phenol/alcohol derivatives is that 
the starting material (9) is commercially available (2,5-dihydroxybenzaldehyde). As outlined in 
Scheme 5-8, the 5-OH group can be selectively protected and then followed by reduction of the 
benzyl alcohol and protection of the phenol/alcohol. Deprotection of the 5-OH, then addition of 
the corresponding alkyl chain at the 5-position, and finally deprotection of the phenol/alcohol 
would yield the necessary precursor for phosphate cyclization. 
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Compound 9 was treated with TBDMSCl and imidazole in DCM at RT, which gave 
compound 10 exclusively as a yellow oil (82.5 %); this selectivity is likely due to a meta-
directing effect of the aldehyde. A reduction of compound 10 with NaBH4 in EtOH at 0 °C 
afforded compound 11 as a white solid. In order to protect the two hydroxyl groups, compound 
11 was treated with 2,2-dimethoxypropane and pTsOH in acetone at RT to give compound 12 as 
a yellow oil. The silyl ether of compound 12 was deprotected by treatment with 
tetraethylammonium fluoride in THF at RT to produce compound 13. Functionalization of the 5-
OH with alkyl ether was carried out via a nucleophilic displacement of the appropriate alkyl 
bromide under basic conditions. Thus, 1-bromotetradecane and K2CO3 were directly added to 
compound 13 in THF at 70 °C and afforded compound 14 as a yellow oil. Finally, the two 
hydroxyl groups of compound 14 were deprotected using 4.0 M HCl in dioxane/THF at RT to 
yield compound 15 as a white solid. All of the compounds prepared were in agreement with 
literature outcomes.
112
    
The final step of this process was to incorporate the cyclized phosphate group. We used 
the procedure developed and shown previously on a small scale (Section 4.2.1). Compound 15 
(30-50 mg) was treated with POCl3 and TEA in THF at -70 °C for one hour, -40 °C for one hour, 
and then warmed to RT overnight. However, the desired product (A3) was not observed, even 
after several attempts (Scheme 5-8). We did not observe any solubility issues with the C14 
substituted precursor. The polar head groups and alkyl chains may form micellar-like complexes, 
which could internalize the reactive groups. This seems unlikely, however, given that THF 
possesses both polar and non-polar solvation characteristics. Due to a lack of compound 15, we 
were unable to carry out this reaction under different conditions. Additionally, trying this 
reaction on a larger scale may also be helpful. 
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Scheme 5-8:  Synthetic pathway to alkyl ether derivatives of cyclic phenol phosphate with 14:0 long side 
chain analogue 3 (A3).  
Reagents and Conditions: i) tBDMS-Cl, imidazole, CH2Cl2, RT, overnight; ii) NaBH4, EtOH, 0 °C to RT, 
2 h; iii) 2,2-dimethoxypropane, pTsOH(cat), acetone, RT, 48 h; iv) tetraethylammonium fluoride, THF, 
RT, 2 h; v) Bromoalkyl (1-bromotetradecane), THF, K2CO3, 70 °C, 24 h; vi) HCl 4.0 M in dioxane, THF, 
RT, 24 h; vii) POCl3, THF, TEA, −70 °C, 1 h, −40 °C, 1 h, RT, overnight. 
15: 
1
H NMR (500 MHz, D2O): δ (ppm) 0.91 (3H, t); 1.28 (20H, m); 1.45 (2H, quin); 1.76 (2H, quin); 
3.90 (2H, t); 4.85 (2H, s); 6.64 (1H, d, J = 2.6 Hz); 6.77, 6.79 (1H, dd, J = 2.6 Hz); 6.83 (1H, d, J = 8.5 
Hz).  
 
5.3 Stability Study  
One concern when assessing mechanism-based enzyme inactivators is the possibility that 
the substrate may spontaneously decompose under the conditions used for the enzyme assay. 
Spontaneous formation of an O-QM outside of the enzyme active site could result in an enzyme 
inactivation that is not the result of the enzyme’s catalytic mechanism. This type of reactive 
intermediate formation would result in diminished target selectivity and is generally undesirable. 
We therefore decided to examine the stability of our compounds in the ATX assay system in the 
absence of the enzyme to confirm that any ATX inhibitory activity that was measured was a 
likely reflection of catalytic activity. We examined the hydrolytic stability of our synthesized 
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cyclic phenol phosphate analogues A1 (unsubstituted cyclic phenol phosphate) and A2 
(methoxy-substituted cyclic phenol phosphate) in TRIS buffer (50 mM) at pH 8.0 and 37 °C. We 
reasoned that these analogues should be acceptable as model compounds for this family as they 
retain the cyclic phosphate group, and any differences in substituent effects from the alkoxy 
groups should be evident in our methoxy derivative (A2). Our stability experiments revealed that 
both analogues were stable under these conditions as no change in substrate peak areas was 
observed over six hours, indicating that A1 and A2 showed stability against non-enzymatic 
decomposition (Figure 5-12 and 5-13 respectively).  
 
Figure 5-12:  Stability study results of A1. 
0.1 mM A1 analogue in TRIS buffer (50 mM; pH 8) over time (h) at 37 λ = 280 nm. 
The experiment was run in triplicate using HPLC to measure change in starting material. The peak area 
under the curve was normalized to the 0.1 mM internal standard (KA-1-09-2). 
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Figure 5-13: Stability study results of A2. 
0.1 mM A2 analogue in TRIS buffer (50 mM; pH 8) over time (h) at 37 
The experiment was run in triplicate using HPLC to measure change in starting material. The peak area 
under the curve was normalized to the 0.1 mM internal standard (KA-1-09-2).  
 
5.4 ATX Inhibition Assay 
 At this time, we have two cyclic phenol phosphate analogues, A1 and A2, and these 
compounds have been submitted to our colleagues at the University of Memphis for assessment 
of their ability to inactivate ATX in vitro. However, they have not yet been able to carry out the 
ATX inhibition assay.  
5.5 Preliminary in Silico Docking Studies of Cyclic Phenol Phosphate 
Analogues with Autotaxin 
 
 After submitting A1 and A2 for ATX inhibition assay, and because we think without the 
long chains they may not be great inhibitors, we are using the docking studies to draw 
comparisons between these analogues and the proposed one (with long side chain C14, C16, and 
C18), to see if our hypothesis agrees with what we expect: that the hydrophobic chain will 
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influence enzyme binding. Therefore, several ligands were docked to the free active site of the 
ATX enzyme (PDB ID: 3NKM) to compare them. The list of ligands consist of (a) LPA with 
different long side chains (14:0, 16:0, and 18:0) as standard; (b) our synthesized analogues A1 
and A2; (c) the proposed alkyl ether derivatives of cyclic phenol phosphate analogues with 
different long side chains (C14, C16, and C18); (d) the proposed acyl derivatives of cyclic phenol 
phosphate analogues (C14, C16, and C18); and (e) the mono-fluorophosphodiesters (C14, C16, C18) 
compounds synthesized by our collaborators as ATX irreversible inhibitors. For good docking 
results, low scores must be assigned to good poses for more favorable binding conformations 
between the ligand and ATX. Table 5-2 shows the results of docking these ligands. We 
compared the scores of ligands with different long side chains and found no major difference 
between them. However, A1 (the unsubstituted cyclic phenol phosphate) and A2 (the methoxy-
substituted cyclic phenol phosphate) show the highest values: -5.0872 and -4.6969, respectively. 
This result indicates that the long side chains of the other ligands play a role in binding to ATX. 
Also, the effect of ester versus ether linkage to the hydrocarbon chain was also evaluated by 
comparing both proposed acyl and alkyl ether derivatives of cyclic phenol phosphate analogues 
with long side chains (C14, C16, and C18), and no major differences were observed between them. 
This indicates that the carbonyl functional group is not required for ATX binding.  
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Table 5-2: Scores of docking different ligands with ATX. 
No. Ligand Name Ligand Structure S* 
ATX-ligand 
complex** 
ATX-ligand 
interaction** 
1 14:0-LPA 
 
-7.8227 Figure 5-14 Figure 5-15 
2 16:0-LPA 
 
-8.8659 Figure 5-16 Figure 5-17 
3 18:0-LPA 
 
-8.5223 Figure 5-18 Figure 5-19 
4 A1 
 
-5.0872 Figure 5-20 Figure 5-21 
5 A2 
 
-4.6969 Figure 5-22 Figure 5-23 
6 
Proposed alkyl ether cyclic 
phenol phosphate (14:0) 
 
-8.5971 Figure 5-24 Figure 5-25 
7 
Proposed alkyl ether cyclic 
phenol phosphate (16:0) 
 
-8.4368 Figure 5-26 Figure 5-27 
8 
Proposed alkyl ether cyclic 
phenol phosphate (18:0) 
 
-8.9798 Figure 5-28 Figure 5-29 
9 
Proposed acyl cyclic 
phenol phosphate (14:0) 
 
 
-8.9927 Figure 5-30 Figure 5-31 
10 
Proposed acyl cyclic 
phenol phosphate (16:0) 
 
 
-8.2032 Figure 5-32 Figure 5-33 
11 
Proposed acyl cyclic 
phenol phosphate (18:0) 
 
-9.2624 Figure 5-34 Figure 5-35 
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No. Ligand Name Ligand Structure S* 
ATX-ligand 
complex** 
ATX-ligand 
interaction** 
12 
(14:0)-p-
monofluorophosphodiester 
 
-8.8739 Figure 5-36 Figure 5-37 
13 
(16:0)-p-
monofluorophosphodiester 
 
-8.7912 Figure 5-38 Figure 5-39 
14 
(18:0)-p-
monofluorophosphodiester 
 
-8.2561 Figure 5-40 Figure 5-41 
*For scoring function, lower scores indicate more favorable poses. The unit for scoring function is kcal/mol 
**All figures can be found in Table 5-3 
 
Table 5-3: List of all figures of ATX-ligand complex and ATX-ligand interaction for each 
ligand. 
No. ATX-ligand complex figure ATX-ligand interaction figure*** 
1  
 
Figure 5-14: ATX-ligand (no.1) complex 
 
 
Figure 5-15: ATX-ligand (no.1) interaction 
O P
O
O
OH
(CH2)13CH3FH2C
O P
O
O
OH
(CH2)15CH3FH2C
O P
O
O
OH
(CH2)17CH3FH2C
 
 
77 
No. ATX-ligand complex figure ATX-ligand interaction figure*** 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-16: ATX-ligand (no.2) complex 
 
Figure 5-17: ATX-ligand (no.2) interaction 
3  
 
Figure 5-18: ATX-ligand (no.3) complex 
 
Figure 5-19: ATX-ligand (no.3) interaction 
4  
 
Figure 5-20: ATX-ligand (no.4) complex 
 
 
Figure 5-21: ATX-ligand (no.4) interaction 
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No. ATX-ligand complex figure ATX-ligand interaction figure*** 
5  
 
Figure 5-22: ATX-ligand (no.5) complex 
 
 
Figure 5-23: ATX-ligand (no.5) interaction  
6  
 
Figure 5-24: ATX-ligand (no.6) complex 
 
 
Figure 5-25: ATX-ligand (no.6) interaction 
7  
 
Figure 5-26: ATX-ligand (no.7) complex 
 
Figure 5-27: ATX-ligand (no.7) interaction 
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No. ATX-ligand complex figure ATX-ligand interaction figure*** 
8  
 
Figure 5-28: ATX-ligand (no.8) complex 
 
Figure 5-29: ATX-ligand (no.8) interaction 
9  
 
Figure 5-30: ATX-ligand (no.9) complex 
 
 
Figure 5-31: ATX-ligand (no.9) interaction 
10  
 
Figure 5-32: ATX-ligand (no.10) complex 
 
Figure 5-33: ATX-ligand (no.10) interaction 
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No. ATX-ligand complex figure ATX-ligand interaction figure*** 
11  
 
Figure 5-34: ATX-ligand (no.11) complex 
 
Figure 5-35: ATX-ligand (no.11) interaction 
12  
 
Figure 5-36: ATX-ligand (no.12) complex 
 
 
Figure 5-37: ATX-ligand (no.12) interaction 
13  
 
Figure 5-38: ATX-ligand (no.13) complex 
 
 
Figure 5-39: ATX-ligand (no.13) interaction 
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No. ATX-ligand complex figure ATX-ligand interaction figure*** 
14  
 
Figure 5-40: ATX-ligand (no.14) complex 
 
 
Figure 5-41: ATX-ligand (no.14) interaction 
 
***   
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CHAPTER 6: CONCLUSIONS 
6.1 Summary and Conclusion  
In summary, our research seeks to prepare and assess a series of acyl and alkyl ether 
derivatives of cyclic phenol phosphate analogues for their ability to function as irreversible ATX 
inhibitors in vitro. Our results demonstrate that the demethylation step for synthesis of acyl 
derivatives of cyclic phenol phosphate analogues did not afford the expected product, either 
directly or after protection of the hydroxyl groups by different groups such as acetyl, benzyl, or 
TBDMS. It is unclear why the methyl group at position C4 of the aromatic ring of compound 1 
cannot be removed under these conditions (Table 5-1). Thus, we conclude that one or more 
structural features of compound 1 prevent the demethylation reaction from occurring. Obviously, 
the proposed synthetic demethylation step proved practically challenging as the expected 
products were not obtained. Therefore, because attempts at demethylation of 1 were 
unsuccessful, our attention turned to the second approach, which was the synthesis of alkyl ether 
derivatives of cyclic phenol phosphate analogues. We attempted a different procedure and 
successfully synthesized A1 (unsubstituted cyclic phenol phosphate) and A2 (the methoxy-
substituted cyclic phenol phosphate). Also, we proposed a different pathway for synthesis of 
alkyl ether derivatives of cyclic phenol phosphate analogues with long side chains (C14, C16, and 
C18), and although we were able to prepare a precursor with C14 side chain, our attempts at 
incorporation of the cyclic phosphate moiety were unsuccessful.  
We also evaluated the stability of the synthesized analogues A1 and A2 under certain 
conditions, and both A1 and A2 were stable. Both analogues have been submitted to our 
colleagues at the University of Memphis for assessment of their ability to inactivate ATX in 
vitro, and we are awaiting these results. 
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Molecular modeling was done by docking a number of potential ATX ligands to the 
active site of crystal structure of mouse ATX. These preliminary results revealed no great 
differences between these ligands. However, both A1 (with no chain) and A2 (with short chain) 
show the highest values (i.e. lowest affinity), which indicate that the long side chains of the other 
ligands play a role in binding to ATX. 
In conclusion, the proposed cyclic phenol phosphates have not been previously prepared, 
and thus they represent a new orientation for the study of ATX inhibitor compounds and may 
lead to the development of new treatments for ATX-related human diseases in the future, 
including cancer. 
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CHAPTER 7: FUTURE RESEARCH DIRECTIONS 
  
At this time, we have synthesized two cyclic phenol phosphate analogues of alkyl ether 
derivatives (A1 and A2). These analogues have been submitted to the Parrill-Baker laboratory at 
the University of Memphis in the United States to determine the ability of these compounds to 
inactivate ATX enzyme in vitro. Completion of the synthesis of alkyl ether derivatives of cyclic 
phenol phosphate analogues with long side chains (C14, C16, and C18) analogues will be needed to 
obtain a complete set for ATX inhibition assay. The synthetic challenge that remained was 
incorporation of the cyclized phosphate group. More of the phenol/alcohol starting material 
(compound 15) possessing long C14 chain alkyl ether could be made and scaled up, as outlined in 
Scheme 5-8, so the phosphate cyclization step could be reperformed. The lipophilicity of 15, due 
to the long side chain, could interfere with the phosphate cyclization reaction. Different 
conditions could be used, such as changing the solvent and temperature. Also, starting materials 
with long side chains (C16 and C18) alkyl ether could be made by using the same synthetic 
pathway for preparing 15 (Scheme 5-8), but using 1-bromohexadecane and 1-bromooctadecane, 
respectively, instead of 1-bromotetradecane. One potential approach to forming the required 
analogues is trying a shorter chain length to see if this works and optimize reaction conditions 
based on this.  
If these compounds show promise, then synthesizing non-LPA analogues of cyclic 
phenol phosphate should be considered and could be other potential directions for this project. 
Because our analogues carry a long aliphatic chain, such long chain based compounds are not 
predicted to afford favorable pharmacokinetics properties. Nevertheless, they are promising leads 
compounds that are able to develop more drug-like inhibitors by structural variations. For 
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instance, the long aliphatic chain can be replaced by more drug-like chains. In our case, a great 
place to start would be HA155 (calculated log P 5.41, MOE) (Figure 2-9). The boronic acid 
moiety in HA155 inhibitor targets the Thr oxygen nucleophile in the ATX active site, whereas 
the hydrophobic 4-fluorobenzyl moiety of the inhibitor targets the hydrophobic pocket 
responsible for lipid binding.
4, 35, 88
 Therefore, replacing the boronic acid with our cyclic phenol 
phosphate group may help the development of new ATX inhibitors for therapeutic use (Figure 7-
1).   
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Figure 7-1: New developed ATX inhibitor.  
 
 
Finally, it would be instructive to confirm that the cyclic phenol phosphate pro-drug is 
indeed converted to an o-QM by ATX in vitro. A common method for determining quinone 
methide formation is via trapping with glutathione and formation of stable adducts which can be 
identified using mass spectrometric techniques.
104
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